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Abstract  
One of the clinical challenges in the treatment of diseases with a discrete distribution is 
the local delivery of active drugs without causing systemic side effects. Doxorubicin, an 
anti-cancer drug, is an example that may cause damage to patients due to its interaction 
with normal cells. Tissue plasminogen activator (tPA) is another active agent whose 
effectiveness is compromised due to its unselective effect on both healthy and 
pathological blood clots.  
 
Thermal sensitive liposome is a drug carrier that is not only able to entrap drug into it 
hydrophilic interior but can also release encapsulated agents upon mild hyperthermia. 
Currently, lysolipid-containing thermal sensitive liposome (LTSL) is a standard 
formulation due to its rapid release behaviour. However,   concerns have been raised 
regarding the negative effect of lysolipid on LTSL stability that results in undesirable 
leakage of encapsulated drug in vivo at physiological temperature.  
 
Therefore, the first aim of the project was to develop a lysolipid-free thermal sensitive 
liposome (TSL) formulation. For this purpose, doxorubicin was adopted as a model drug.  
The amount of doxorubicin molecules encapsulated in TSL (0.0123 mg of doxorubicin 
per 1 mg of lipid) was 2 times the amount in the existing publications (0.05 mg of 
doxorubicin per 1 mg of lipid ). This was done by optimizing the incubation temperature 
(36oC for 1 hour) during preparation of TSL. When heated from room temperature to 42 
oC, doxorubicin-encapsulated-TSLs release encapsulated doxorubicin molecules faster 
than their LTSL counterpart. This may result from a higher membrane-bound doxorubicin 
concentration in dox-TSLs.   
 
The second objective of the project was to develop a tPA-encapsulated TSL (tPA-TSL) 
formulation that can release encapsulated tPA molecules under hyperthermia condition. 
It has been demonstrated that the developed tPA-TSL was able to release encapsulated 
tPA upon 7 minute heating at 45oC.  The release of tPA molecules was expected to 
result from irreversible destruction of liposome upon heating, as was demonstrated by 
reduction of particle size.  
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Chapter 1. Introduction  
 
1.1. Historical context and the emergence of modern medicine 
 
Drug, a general term that describes the substance humans consume for curing disease, 
has evolved with the development of human civilization since antiquity. In the past 
century, the world level life expectancy increased from 47 years in 1950-1955 to 68 
years in 2005-2010 (Zhao. 2011) and advances in medicine is a crucial contributor to the 
increase of well state of human being. In the world we are living today, the magic bullet 
concept (to be detailed below) is the predominant thinking behind the development of 
modern medicine. This is especially the case when a detectable pathogen is the cause 
of a disease and pathogen-specific toxin is administered to patients in order to destroy 
the pathogen without harming the host.  While this may seem obvious to people living 
today, the magic bullet concept was not established until the beginning of the 20th 
century as a cross-field product that benefited from advances in organic chemistry, 
synthetic chemistry, pharmacology and parasitology (Bosch. 2008).  
 
Prior to the acceptance of the magic bullet concept, drug was predominately guided by 
our cultural understanding of the nature of the cosmos, disease and human body. In 
Europe, since the Black Death that killed nearly one-third of the European population, 
theories other than superficial explanations (e.g. witchcraft, divine judgment) had been 
proposed to explain why the plague occurred with an attempt to cure diseases. In the 
late 15th century (100 years after the Black Death), syphilis (also known as “sexual 
plague”) became the major killers in Europe since renaissance time till the early 20th 
century (Kelly. 2009) and is still portrayed in some culture as a divine judgment from 
God due to its sexual transfer nature (Bosch. 2008).   
 
Prescribed in the canon of medicine (the most influential medical textbook in medieval 
time), mercury was the standard treatment for syphilis before the 18th century, which 
gave rise to the famous saying “a night in the arm of venus leads to a lifetime on 
mercury”, demonstrating both the false shame brought to the infected people and the 
length of the treatment (Semaan et al. 2006).   Sadly, oral intake of mercury caused 
severe side effects to the treated patients (e.g. tremors, impaired cognitive skills); the 
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cure rate was extremely low and syphilis still claimed peoples’ life  (e.g. Vladimir Lenin, 
based on official report) as late as the early 20th century (Service . 2000). In the modern 
era, patented arsenic containing solutions (historically called tonic for their wide range of 
“curable” diseases) became an alternative remedy of syphilis other than the more toxic 
mercy (Jolliffe. 1993). When looking back into the history, the two major medicines used 
to treat syphilis share the same problem: using medicine without acknowledging the 
disease-causing target.  
 
In the early 20th century, the major development in parasitology not only allowed 
diagnosis of the true cause of some of the well-known “disease” (e.g. African sleep 
sickness is caused by the infection of Trypanosoma brucei (Goddard 2013), syphilis is 
caused by Treponema pallidum), but also opened the door for medical research by 
enabling the direct effect of drug to be assessed. In 1909, Paul Enrich, the founding 
father of therapeutic pharmacology, successfully synthesised Arsphenamine (marketed 
as Salvarsan), a Treponema pallidum-targeting chemicals with two well defined 
characteristics:  parasitotropic but not organotropic (i.e. drug that harms the parasitic 
invader without harming the host) (Witkop. 1999.). In 1910, he published the rationale 
behind the development of an ideal version of parasite—targeted medicine:  
 
“These antibodies are exclusively ‘parasitotrop’ and not ‘organotrop’, and hence it can 
be no surprise that they find their target as a kind of magic bullet. In this way, I also 
explain some of the marvellous cures of that [therapeutic] direction. It is therefore eo 
ipso self-evident, that the serum method must be ceteris paribus superior to every other 
type of therapy precisely through the pure parasitotropy of these medical 
substances” - stated by Paul Ehrlich in Boyer. 2013 
 
Since its introduction to the medical world, the concept of magic bullet had revolutionized 
the strategy people used to develop medicine: from finding the chemicals that can 
relieve the symptom of the disease to finding the magic target and relevant magic 
target.  In the field of antibacterial drug development, thanks to the distinctive cell 
structure between mammalian eukaryotic and prokaryotic bacteria, the antibiotic 
(including penicillin) developed under the magic bullet strategy had saved numerous 
human life from once life-threatening infectious diseases.  
16 
 
However, finding the magic target is the pre-condition of rational design of the magical 
bullet. Without it, magic bullet will lose its “not organotropic” features and compromise its 
efficacy at the disease-causing site. As a result, while drug may still be able to kill the 
target effectively, it could also damage normal cells and result in undesirable side effects 
or render the treatment completely ineffective.  
 
Cancer and life-threatening blood clots are the two main areas where the development 
of magic bullets is compromised by the lack of ideal magic sites. In this project, both 
areas will be explored.  
 
 
1.2. Current stage of magic bullet for tumour treatment 
 
Tumour is the end product of abnormal growth or division of cells and malignant tumour 
(or cancer) is now the major cause of death of elderly people (50-74 years old) in the 
United Kingdom (Cancer mortality by age, available from 
http://www.cancerresearchuk.org). Since tumour cells are originated from normal cells, 
no magic targets that are distinctively present in tumour cells have been found. 
Consequently, current strategy of tumour treatment is mainly focused on improving the 
chances of drug deposition to tumour rather than normal cells by making use of the 
abnormal up-regulation of various receptors (most notability epidermal growth factor 
receptor, EGFR) (Normanno et al, 2006) or the hyper vascular permeability of tumour.  
 
In 1985, Mike Sporn and Anita Robert discovered that various types of  carcinoma 
tumour (e.g. gastric, breast, colorectal, ovarian, cervical, bladder and oesophageal 
cancer) have up-regulation levels of EGFR (a  cell-surface receptor that regulates cell 
growth and proliferation) (Sporn and Robert. 1985). This discovery spurred the 
development of EGFR receptor-targeted drugs. Since the first EGFR inhibitor was 
approved to treat chronic myeloid leukaemia (CML) in 2001, imatinib®, has received 
positive reception and was regarded as a “miracle drug”. In one of the most important 
clinical trials carried out by Brian and his colleagues, 53 out of 54 patients had their 
white blood cell counts restored to the normal range within 1 month of treatment, with 
nearly 90% of patients survived 5 years after treatment (Pray. 2008). For their discovery, 
Drucker and his colleagues (the team behind the invention of imatinib®) received the 
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Lasker-Debaker clinical medical research award for “converting a fatal cancer into the 
manageable condition” and “Japan prize” for development of “therapeutic drug 
targeting cancer-specific molecules”.  
 
However, as the drug was designed to target EGFR, successful therapeutic outcome of 
imatinib® treatments depends on the quality of its target (i.e. the extent of up-regulation 
of EGFR and level of its mutation). For instance, while most CML patients have positive 
up-regulated EGFR levels, only 15% of patients with invasive breast cancer have up-
regulated level of EGFR (DiGiovanna et al. 2005) and 30% of patients with non-small-
cell-lung cancer (NSCLC) have the required level of EGFR expression (Pirker.  2012). In 
one of the latest phase III clinical trials, NSCLC patients who had low levels of EGFR 
expression did not show survival benefit from cetuximab®, a recently designed EGFR 
inhibitor (Pirker. 2012).  
 
A serious drawback of imatinib® is its negative influence on immunoregulatory system: 
through the same mechanism of action as it inhibits tumour proliferation, imatinib® 
substantially reduces the proliferation of activated T cells (responsible for cell-mediated 
immunity) (Seggewiss et al 2005). As a result, for patients who are treated with imatnib®, 
even vaccine may become the source of infection.  
 
Another major discovery of target site for tumour is made on the tissue, rather than 
molecular level. In 1984, Hiroshi Maeda of Kumamoto University discovered that nano-
sized particles could accumulate in tumour (Hoffman. 2008). This tumour specific 
phenomenon is known as the enhanced permeability and retention effect (i.e. EPR 
effect) which can be utilized to develop specialized particles for tumour treatment. In 
parallel, long circulating nanoparticle developed in 1987 has significantly increased the 
circulation time of nanoparticles, fulfilling the condition required for satisfactory tumour 
accumulation (24-hour circulation time is needed to achieve maximum nanoparticle 
accumulation in tumour) (Working et al. 1994). These two discoveries initiated the 
development of EPR-guided nanoparticles which can incorporate molecules ranging 
from toxin (chemotherapy, to be detailed below) to the latest tumour-specific gene 
therapeutics for tumour treatment. Similar to EGFR targeted drugs, the effectiveness of 
EPR-guided nanoparticles depends on the quality of the target (the leakiness of tumour 
blood vessel), a condition that till recently has been proved to be highly heterogeneous 
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among patients and is considered to be the main reason for the diverse clinical results of 
EPR-guided nanoparticles (Prabhakar. 2013).      
 
 
1.3. Current stage of magic bullet for blood clot lysis 
 
Blood clot formation (i.e. thrombogenesis) is an essential function in human body that 
enables the rapid repair of injured blood vessels. As the end product of a complicated 
cascade reaction (i.e. coagulation process), a polymerized-fibrin blood clot is eventually 
formed at the damaged vessel, the formation of which prevents the loss of blood upon 
vascular injury and serves as a provisional matrix in subsequent tissue repair (Yakovlev 
et al. 2000). The damaged part of the vessel is then recovered after the dissolution of 
initially formed blood clot through fibrinolysis process (blood clot lysis): Plasmin and 
tissue plasminogen activators (tPA) are two types of proteins that account for the 
fibrinolysis activity in the vessel. Through activation, plasminogen (a precursor enzyme 
of plasmin) is converted into plasmin, which dissolves the fibrin network (the building 
block of blood clot) and restores blood flow in the vessel (Yakovlev et al. 2000).  TPA, 
produced by endothelial cells, is responsible for the conversion from plasminogen to 
plasmin.  If the balance between fibrinogenesis and fibrinolysis is tilted towards the 
former, excessive blood clots may be formed in the vessel resulting in reduction of blood 
flow.  Stroke and myocardial infarction (MI) are two of the most severe consequences of 
pathophysiological blood clot formation in a large blood vessel (Francis et al. 1987, 
Meunier. et al. 2007). Clinically, administration of tPA is the only accepted method to 
treat acute ischemic stroke and myocardial infarction in the U.S.A and U.K.  
 
On the other hand, as tPA can also dissolve hemostatic blood clots that are present in 
the vessel, administration of tPA may result in internal bleeding of the affected area or 
areas remote from the clot (Ganguly et al. 2005, Ganguly et al. 2006).  
 
1.4. Emergence of external energy field-triggered drug delivery system 
 
External energy field-triggered drug delivery system (DDS) is defined as a drug delivery 
strategy that is able to selectively release drug at the desirable site when exposed to an 
external energy field. It has become a branch of clinically-applicable technique in the 
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past 30 years. The concept of drug delivery strategy was firstly introduced by Yatvin et al 
(Yatvin et al. 1978): inspired by the early work of Papahadjopoulos et al 
(Papahadjopoulos et al. 1973), Yavin and his colleagues demonstrated for the first time 
the ability of liposome (a type of nanoparticle composed of phospholipids with a 
hydrophilic interior that can be used to entrap drug molecules) to selectively release 
encapsulated model drug (i.e. neomycin) in response to temperature rise from 37 to 
420C, which led to a 100 time increase in local drug concentration (Yatvin et al. 1978). 
This type of nanoparticle was defined by Yatvin as thermal sensitive liposome  (Yatvin et 
al. 1978).  Apart from suggesting tumour and local infection being the possible 
applications of thermal sensitive nanoparticles, Yatvin also described the core concept 
and benefit of thermal sensitive liposome compared with conventional drug treatment 
(Yatvin et al. 1978):   
 
“On passing through the heated area in the circulation, the liposome would be expected 
to release their contents at a greater rate than elsewhere and thus to develop higher 
local concentrations.  ”- from Yatvin et al. 1978 
 
In other words, by increasing the temperature of desirable target in the body, drug can 
be locally released in response to temperature rise. This will greatly benefit patients who 
cannot be effectively treated by the magic bullet strategy due to the lack of a magic 
target, which is the case for blood clot-suffering patients or tumour patients who lack 
sufficient up-regulation of EPR and EGFR. For these patients, external energy field-
triggered drug delivery systems offer the advantage of local release of drug without the 
need for a magic target.  
 
In parallel with the emergence of thermal sensitive liposome,  high intensity focused 
ultrasound (HIFU)  was developed as a non-invasive surgical technique and became 
clinically available in 1990 (Hynynen et al. 1990):  Generated by a transducer, multiple 
ultrasound waves can provide localised heating to a specifically targeted area as a result 
of added intensity of multiple wave interactions, while the rest of the body is left 
unaffected due to the relatively low wave intensity of individual waves (Haar et al. 2007).  
HIFU has been applied as an external energy source to trigger the local release of drug 
from thermal sensitive liposomes (de Smet et al. 2011, de Smet et al. 2013, Dromi et al. 
2007, Grull et al. 2012).   
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Radio frequency ablation (RFA) is another clinically available heating method that has 
been used as an external energy source to trigger local release of drug from thermal 
sensitive liposomes (Hong et al. 2013, Poon and Borys. 2009, Poon and borys. 2011).  
Unlike HIFU, RF heats up the body tissue by directly contacting the target area with a 
heating probe, delivering high frequency current and increasing the temperature of the 
targeted area (Haemmerich et al. 2002).  Aside from its invasive nature, RFA does not 
have the ability to accurately control the temperature of heated area at the precision of 
HIFU. As a result, when RFA is used as a heating source, the affected area experiences 
a wider range of temperatures (Gasselhuber et al . 2010) when compared with the 
narrow range generated by HIFU (Dromi et al. 2007).  
 
Although other DDS exists that can be triggered by different external sources (e.g. 
ultrasound, electric field, magnetic field, etc), thermal sensitive liposome is the only 
external energy field-triggered drug delivery strategy that has reached the clinical stage 
so far (Landon et al. 2011).  
 
1.5. Aim of the project  
 
Currently being considered as a crucial component in most thermal sensitive liposome 
formulations, lysolipid has been reported to be a drug release accelerator that can 
influence both the rate and extent of drug release (Anyarambhatla, and Needham. 1999. 
Mills and Needham. 2005). As a result, lysolipid-containing thermal sensitive liposome 
(i.e. LTSL) is currently the gold-standard formulation (Needham et al. 2013. Poon and 
Borys. 2009, Tagami et al. 2011). However, concerns have been raised regarding the 
negative effect of lysolipid on the stability of LTSL that has been found to result in 
undesirable leakage of encapsulated drugs in vivo at physiological temperature (Al-
Ahmady et al. 2012, Li et al. 2013, Hossann et al. 2012 ).  Furthermore, such 
undesirable leakage was predominantly reported in doxorubicin-encapsulated LTSL, a 
well-studied formulation with strong stability due to the formation of doxorubicin crystal 
within the liposome (to be detailed in section.3.2.2.3). Hence, due to the fact that 
majority of small molecules lacks the ability to form organized and stable crystals, the 
extension of LTSL to other therapeutic small molecules is limited.  
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On the other hand, the lysolipid free formulation (e.g. DPPC:DSPE.2000) has been  
found to lack the ability to rapidly release encapsulated doxorubicin. The retarded 
doxorubicin release behaviour reported in the literature is summarized in Table 1.1. 
 
 
 
Table 1.1. Summary of reported doxorubicin release behaviour of DPPC:DSPE.2000 
formulation in the literature 
Formulation Extent of doxorubicin 
release in 10 min (%) 
Reference 
DPPC:DSPE.2000 ~20 Chiu et al. 2005 
~25 Needham et al. 2013 
~22 Banno et al 2010 
  
 
More recently, however, this view has been challenged by the demonstration that 
lysolipid free thermal sensitive liposomes can rapidly release 70% of encapsulated 
cisplatin (another anticancer agent) at a rate similar to its LTSL counterpart (Woo et al. 
2008). Moreover, owing to the absence of lysolipid, cisplatin-encapsulated 
DPPC:DSPE.2000 liposomes are more stable in the circulation compared to its LTSL 
counterpart (Woo et al. 2008). However, as cisplatin was encapsulated as free drug 
molecules (cisplatin cannot be encapsulated through pH gradient and does not form 
crystal), it might be reasonable to speculate that doxorubicin-encapsulated 
DPPC:DSPE.2000 would not be able to  release encapsulated doxorubicin as rapidly as 
its cisplatin-encapsulated counterpart due to the formation of doxorubicin crystals. 
Hence, the first aim of the project is to confirm the release pattern of doxorubicin-
encapsulated DPPC:DSPE.2000 liposome. By doing so, the application of 
DPPC:DSPE.2000 liposome may be expanded to other small therapeutic molecules that 
can form a stable complex within the liposome by increasing the stability of membrane at 
physiological temperature. Doxorubicin is selected as a model drug in the project due to 
the extensive literature on its release behaviour from DPPC:DSPE.2000 liposome. On 
the other hand, as DPPC:DSPE.2000 liposome often have a low  doxorubicin 
encapsulation efficiency compared with its non-thermal sensitive counterparts (Chiu et 
al. 2005), effort has also been made to increase the doxorubicin loading capacity 
of DPPC:DSPE.2000 formulation: As long as the presence of doxorubicin molecules 
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does not compromise the integrity of liposome membrane, a higher amount of 
encapsulated doxorubicin per lipid (drug to lipid ratio D/L) can help reduce the undesired 
leakage of encapsulated doxorubicin at physiological temperature (Jonhnston et al. 
2008). Hence a higher D/L ratio is a desirable property of doxorubicin-encapsulated 
DPPC:DSPE.2000 liposomes . 
 
The other aim of the project is to expand the catalog of feasible drug for thermal 
sensitive liposome to high molecular weight protein-based therapeutics. In the 
thesis, tPA is used as a model drug not only because of its high molecular weight, but 
also because tPA is a thrombolytic agent which is effective at treating blood clots in  
myocardial infarction and acute ischemic stroke.  As such, it is a good example of cases 
where the development of magic bullet is extremely hard as a result of non-differentiable 
structure between pathological and hemostatic blood clots. Prior to the application of 
expansive tPA, however, streptokinase (another widely used thrombolytic agent) is 
selected as a model drug due to its low cost and yet similar mechanism of action.  
 
In summary, the objectives of the thesis are: 
 
 Development of lysolipid-free TSL that is able to encapsulate  doxorubicin  
- Improve the amount of doxorubicin encapsulated in DPPC:DSPE.2000 liposome 
- Determine the thermal sensitivity of doxorubicin-encapsulated DPPC:DSPE.2000 
liposome 
 
 
 
 Feasibility study of thrombolytic agent-encapsulated thermal sensitive liposome 
- Determine the feasibility of thermal sensitive liposome  to encapsulate and 
release streptokinase 
- Determine the feasibility of thermal sensitive liposome to encapsulate and 
release tPA 
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1.6. Outline of the thesis    
 
Chapter 2. Literature review: this chapter introduces the drug delivery system 
developed for the treatment of tumour and blood clots.  
 
Chapter 3. Preparation of simple and stable dox-TSL with high D/L ratio for the 
treatment of solid tumour:  In this chapter, work on increasing the encapsulation of 
doxorubicin in DPPC: DSPE.PEG.2000 liposomes are described in detail.  One of the 
properties of liposomes, Doxorubicin/lipid ratio was determined and compared with 
existing publications.  
 
Chapter 4. Preparation of simple and stable dox-TSL with high D/L ratio for the 
treatment of solid tumour:  In this chapter, hydrodynamic diameter and phase 
transition temperature of DPPC: DSPE.PEG.2000 liposomes that encapsulated with 
doxorubicin molecules have been determined. The release rate of encapsulated 
doxorubicin both from lysolipid-free thermal sensitive liposomes and their lysolipid-
containing counterparts was determined using two heating methods.  
 
 
Chapter 5. Development of tissue plasminogen activator-encapsulated DPPC: 
DSPE.PEG.2000 liposome (tPA-TSL) for thrombolysis:  This chapter describes the 
development of tPA-TSLs.  TPA to lipid ratio, hydrodynamic diameter and phase 
transition temperature of tPA-TSLs have been determined. The ability of tPA-TSLs to 
thermally release encapsulated tPA molecules was determined at 45 oC 
 
Chapter 6. Conclusion: In this chapter, the main findings and limitation of the work  
presented in this thesis are summarized. This is followed by a discussion of the 
limitations associated with the analytical methods used in the project.  At the end of the 
chapter, future works are proposed for further optimization of the formulations and 
testing of the proposed hypothesis.    
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Chapter 2. Literature review 
 
2.1. Clinical application of doxorubicin in anticancer chemotherapy and 
development of doxorubicin-drug delivery system 
The use of chemotherapy in cancer treatment can be traced back to the middle of the 
last century:  tested by Louis Goodman and his colleagues, nitrogen mustards, a 
derivative of the dangerous mustard gas (used as chemical weapon in the first world war) 
was first tested clinically for treatment of various cancers in the 1940s (Joensuu. 2008).  
In the 1950s, inspired by the discovery that antibodies could be produced from bacteria, 
collaborative studies were carried out by two groups of researchers from France and 
Italy in order to find an anticancer compound that could be produced by bacteria (Weiss  
1992). Derived from Streptomyces (a soil-based microbe), daunorubicin (shown in 
Figure 2.1), the first anticancer chemotherapy compound of the anthracycline family was 
discovered. Later, the more powerful compound, doxorubicin (also shown in Figure 2.1), 
was produced by a mutant strain of Streptomyces by the same research group 
(Lomovskaya et al. 1999). The main mechanism of action of doxorubicin and other 
anthracycline chemotherapy is the inhabitation of cell growth through intercalating the 
base pairs of DNA/RNA strands (Rubin and Hait. 2000). However, as doxorubicin cannot 
distinguish tumour cells from normal cells with a fast growth span, the administration of 
doxorubicin also hinders the production of fast growing normal cells. This includes the 
production of red and white cells, leading to the occurrence of anaemia and neutropenia 
(Schwartz et al. 2005). Cells composed of skin, hair, and the gastrointestinal tracts are 
also the likely target of doxorubicin due to their rapid growth rate (Schwartz et al. 2005). 
Furthermore, the main serious side effect of doxorubicin is its cardiotoxicity which may 
cause congestive heart failure (Minotti et al. 1999). While the actual mechanism of its 
cardiotoxicity is still unknown, two hypotheses have been proposed to explain the route 
through which doxorubicin causes heart damage:  
 Production of free radicals:  Catalyzed by various reductase enzymes, 
doxorubicin (and other anthracycline) is transformed into a semiquinine-free 
radical that eventually produces .OH, a potent free radical that can damage heart 
cells (i.e. cardiomyocytes) through oxidation (Xu et al. 2005). In addition, the 
25 
 
presence of free radicals is also responsible for the disruption of cardiac gene 
expression program and reduces the production of several important proteins 
and enzymes (Akimoto et al. 1993).  
 
 Formation of harmful metabolite: Doxol is a hydroxyl metabolite formed by 
cytosolic enzyme. It was detected within the cardiomyocytes of postmortem 
tissue from patients who had previous undergone anthracycline treatment 
(Minotti et al. 1999). Such a metabolite is able to impair cardiac contraction and 
relaxation through affecting the myocardial energy metabolism and ionic gradient 
movement (Minotti et al. 1999).  
 
 
 
Figure 2.1.The structure of doxorubicin and its ancestor molecule daunorubicin. The 
desirable and undesirable targets of doxorubicin are also demonstrated:  doxorubicin 
damages the tumour and normal fast growing cells through DNA/RNA binding. 
Doxorubicin causes heart cell damage mainly through the production of free radicals and 
hydroxyl metabolite.  
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2.2. Development of EPR-based doxorubicin-drug delivery system  
 
Irrespective of its undesirable victims (i.e. normal fast growing cells or cardiomyocytes), 
it is apparent that DNA/RNA binding of normal cells, production of free radicals and the 
metallization of doxorubicin require the direct contact between doxorubicin and specific 
enzyme or target. Hence, by shielding doxorubicin from its potential victims or interacting 
enzymes, the harmful side effect of doxorubicin can be avoided. In 1984, a group led by 
Maeda discovered that the high permeability of solid tumour (i.e. EPR effect) could be 
exploited for drug accumulation (Iwai,.1984). However, in order to make accumulation of 
the drug possible through EPR effect, a longer circulation time of around 24 hours 
(Working et al.1994) and an ideal particle size (~100 nm) are needed (Nagayasu et al. 
1999). Based on these criteria, two drug delivery systems (DDS) have been developed 
with the aim to maximize the availability of doxorubicin to tumour cells whilst reducing its 
toxicity by avoiding interaction between doxorubicin and healthy cells:  
 Doxorubicin-polymer conjugate nanoparticles (Masayuki et al. 1990) 
 Doxorubicin-encapsulated nanoparticle using liposome as a carrier (Barenholz. 
2012) 
The effectiveness of these doxorubicin DDSs depends on two factors:  
 The extent of doxorubicin-DDS deposition in the tumour 
 Availability of free doxorubicin molecules at tumour site.   
 
2.2.1. Doxorubicin-polymer conjugate nanoparticles 
2.2.1.1. Drug-polymer conjugates and their application to doxorubicin 
 
Drug-polymer conjugates are a type of DDS that aims to increase the effectiveness of 
drug by directly attaching polymer molecules onto drug molecules and is the first type of 
DDS that has been applied to toxic chemotherapy (Kopecek and Kopeckova. 2010). 
Polyethyleneglycol (PEG, shown in Figure 2.2) was the first polymer used to conjugate 
therapeutic molecules and was initially used by Davis et al (Davis. 2002) to reduce the 
adverse immunological response of proteins of non-human origin (e.g. insulin). It was 
proposed by Davis that, by conjugating protein with a hydrophilic polymer, the 
undesirable interaction between the immune system of human and therapeutic proteins 
can be prevented (Davis. 2002). Hydrophilic PEG was chosen both as a result of their 
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non-immune nature and the presence of terminal hydroxyl group that is available for 
linking proteins (Davis. 2002). Surprisingly, while fulfilling their main purpose, PEGlyation 
of the protein also increased the circulation time of protein (Davis. 2002). Unfortunately, 
these pioneering techniques were never used to conjugate doxorubicin.     
 
Figure 2.2. Molecular structure of Polyethyleneglycol, PEG, the first polymer for 
therapeutic conjugation. The terminal group is available for drug conjugation.  
 
Independently, hydroxypropylmethacrylamide, (HPMA, see Figure 2.3) a novel synthetic 
polymer with a methylene backbone and a stable amide side chain, was first synthesized 
in the 1970s (Kopecek and Baẑilová et al. 1973). Compared with drug decorated by 
PEG, HPMA was intentionally developed as a cell selective drug delivery system with 
the required multifunction:   
 Selectively targeting cells with a surface attachment of cell targets (e.g. galactose, 
hepatocytes targeting, etc.): A relatively high MW of HPMA makes endocytosis of 
the cell the only pathway for drug uptake, rather than by diffusion (as is the case 
for small molecules). With the help of cell-targeting molecules, the drug has an 
increased chance of uptake by tumour cells.    
 
 Ability to free drug from polymer conjugate:  Using enzyme degradable 
oligopeptides as a link between the polymer backbone and drug molecules, the 
drug can be “released” from its polymer-conjugate form upon interaction with 
specific enzymes.  
In 1983, a specially designed oligopeptide which is degradable only by lysosome was 
synthesized (Kopecek and Kopeckova. 2010). This enabled conjugate drug molecules to 
remain in an inaccessible state before they reached the cytosolic structure of cells 
(Rejmanová P et al. 1985). In 80s, the first doxorubicin-polymer conjugate (doxorubicin-
HPMA, see Figure 2.3) was patented (Rihova et al. 1985). With its ability to add cell-
targeting group, doxorubicin-HPMA has become a good candidate for an effective 
tumour-targeting doxorubicin delivery system.  
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Figure 2.3. Molecular structure of hydroxypropylmethacrylamide, HPMA, and the first 
doxorubicin-polymer conjugate (adapted from Kopecek and Kopeckova. 2010). The link 
between HPMA backbone and doxorubicin was specially designed to be broken only by 
lysosome.  
 
 
 
2.2.1.2. Doxorubicin-polymer conjugate nanoparticle 
 
Irrespective of the detailed structure of the drug-conjugate, a short half-life (h1/2 ) was a 
major drawback in the early stages of drug-conjugate development as increasing h1/2 of 
the drug was not the initially-intended purpose of designing a drug-polymer conjugate. 
For instance, HPMA-doxorubicin has a h1/2  of only 1.8 hours (Vasey et al. 1999). This is 
largely due to the low MW (25KDa) of the HPMA-doxorubicin (Loadman et al. 1999) 
which is readily filtered out of the circulation by renal excretion (cut off range <60 KDa).  
Hence, drug-conjugates can hardly benefit from the discovery of EPR effect as a result 
of their small size and short circulation time. With an aim to overcome the short half-life 
of drug-polymer conjugates and their small particle size, the first doxorubicin–
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incorporated polymeric nanoparticle was invented in the 90s. The main component of 
the nanoparticle is the newly synthesized poly(ethylene glycol)-poly (aspartic acid ) block 
co-polymer,  an amphiphilic polymer with PEG as hydrophilic group and poly aspartic 
acid as hydrophobic group that can conjugate with doxorubicin (Masayuki et al. 1990). 
Due to their amphiphilic nature, the polymers form micelles in the aqueous system and 
shield poly aspartic acid along with doxorubicin from exposure to the circulation 
(Masayuki et al. 1990). Owing to its large particle size, the half-life of such doxorubicin-
conjugate was significantly increased compared with its drug-conjugate counterpart 
(Masayuki et al. 1990).  The actual release mechanism and detachment of doxorubicin 
from polymer, however, are not fully understood. More recently, a nanoparticle 
composed of HMPA-doxorubicin has been developed and the resultant formulation not 
only offers a long half-life but also has the ability to specifically release doxorubicin upon 
reaching the cytosol of cells (Etrych et al. 2011).  
 
 
2.2.2. Doxorubicin-encapsulated nanoparticle using liposome as carrier  
 
Liposomes are artificial bilayer vesicles composed mainly of a mixture of phospholipids, 
which are essentially an amphiphilic substance with a hydrophilic polar phosphate head 
and two hydrophobic hydrocarbon tails (Drummond et al. 1999). After following an 
appropriate preparation procedure, vesicles with a hydrophilic interior that is isolated 
from the exterior water environment by a bilayer composed of phospholipid molecules, 
can be produced (Barenholz 2001). Using this bilayer as a barrier, it has already been 
shown in the early 60s that hydrophilic molecules can be encapsulated into the 
hydrophilic interior of the liposome (i.e. liposomal doxorubicin) to prevent undesirable 
doxorubicin exposure (Bangham et al. 1965). In stark contrast to the fast moving pace of 
drug-polymer conjugate research in the 70s, however, development of liposome-based 
drug delivery systems has been slow since the early finding in the 50s. It was not until 
the 1980s that major discoveries had been made which catalysed the development of 
nanoparticle as an ideal doxorubicin carrier:   
 Invention of extrusion method for the preparation of liposomes in 1979:  A 
liposome reduction technique that can produce liposome with very 
homogenously distributed particle sizes ranging from 100 - 400 nm (Olson et al. 
1979).  
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 Discovery of EPR effect in 1984: The group led by Maeda discovered that the 
high permeability of solid tumour can be exploited for drug accumulation (Iwai et 
al. 1984). Later on, the ideal size of particles was discovered to be 100 nm, a 
size that enabled particles to avoid renal secretion and liver uptake, whilst being 
able to penetrate into the tumour region (Nagayasu et al. 1999).  
 
 Invention of long circulating liposomes in 1987 and 1990: Liposomes 
incorporated with specially designed lipids (i.e. gangliosides and sphingomyelin) 
were first developed in 1987 and were found to be able to significantly increase 
the h1/2 of the liposomes in circulation to 24 hours (Allen et al. 1987). In 1990, 
liposome was, for the first time, surface decorated with a polymer (i.e. PEG) 
which increased the h1/2 of liposome to ~24 hours (Klibanov et al. 1990). This 
formulation was later referred to as stealth liposome.  
 
 
 Invention of pH gradient encapsulation method for doxorubicin in 1990: This 
encapsulation method creates a cross-membrane pH gradient that drives 
doxorubicin to move into the interior of liposome. The amount of encapsulated 
doxorubicin in doxorubicin-encapsulated liposome is thus 4 times higher than 
doxorubicin-polymer conjugates (Madden et al. 1990). 
On the basis of these inventions and discoveries, Doxil®, the first doxorubicin-
encapsulated liposome claimed to be able to “selectively accumulate doxorubicin loaded 
liposome into the tumour”, was developed in the early 90s (Barenholz  2012). The 
structure of Doxil® is illustrated in Figure 2.4.  
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Figure 2.4. Demonstration of doxil
®
, the first doxorubicin-encapsulated nanoparticle, 
adapted from http://www.doxil.com. Crystalized doxorubicin through a pH gradient method 
was encapsulated in the interior of liposome. 
 
As the first doxorubicin loaded nanoparticle, Doxil® has become a commercial success 
and ranked the second bestselling medical product in the US after launch. When 
compared with drug-conjugate, its compatibility as a passively accumulative nanoparticle 
and far superior doxorubicin loading make Doxil® a stronger competitor than doxorubicin-
conjugate nanoparticles. The most serious problem with Doxil®, however, is the lack of a 
suitable approach to release the encapsulated doxorubicin after accumulation. This has 
hampered the in vivo effectiveness of Doxil (Kong et al. 2000).   
 
In 1980 (about the same time when the extrusion method was developed), a novel 
liposome based-drug delivery system , pH sensitive liposome was first proposed with an 
intention to make use of the low pH environment of solid tumour: using a pH sensitive 
liposome (i.e. n-palmitoyl homocysteine), encapsulated model molecules were able to be 
rapidly released on a low pH environment (Yatvin et al. 1980). In theory, the combination 
of Doxil® and pH sensitive liposome should be able to resolve the doxorubicin release 
issue. However, the major hurdle of the utilization of a pH sensitive liposome as a 
doxorubicin carrier is the lack of a suitable doxorubicin encapsulation method that can 
achieve satisfactory loading: as pH gradient method and more advanced Mn or Copper 
doxorubicin-complexation method all require the establishment of a low pH liposome 
interior as the driving force for doxorubicin encapsulation (Cheung et al. 1998).  Thus pH 
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sensitive liposomes do not currently have a high loading efficiency due to their pH 
sensitive nature.  
 
 
2.3. Thermal sensitive nanoparticles for doxorubicin  
 
Both drug delivery methods described above aim to deliver doxorubicin in two 
synchronized steps. 
 Deposition of doxorubicin-carrying nanoparticles through EPR-based tumour 
accumulation   
 Rapid release of encapsulated-doxorubicin upon reaching the target site.  
As the efficiency of doxorubicin molecules to kill tumour cells is directly related to their 
local concentration, most of nanoparticle-based DDSs aim to release the 
encapsulated/conjugated doxorubicin as soon as the nanoparticles reach the tumour 
region despite their different release mechanisms (Bertrand et al. 2010). This strategy 
however, may cause the tumour to be exposed to inadequate doxorubicin 
concentrations over a long time period and this may increase the likelihood of the tumour 
developing multi-drug resistance. This, ironically, is the consequence of a combination of 
slow tumour accumulation of nanoparticles and their rapid release of doxorubicin. For 
instance, even with an ideal particle size, liposomal doxorubicin is progressively 
accumulated in the tumour region during its circulation in vivo and its concentration in 
the tumour is estimated to reach a peak 24 hours after administration (Uster et al. 1998). 
In contrast, most of spontaneously-triggered stealth liposomal doxorubicin vesicles are 
designed to rapidly release encapsulated doxorubicin upon reaching the tumour region 
(Bertrand et al. 2010). As a result of such slow accumulation and rapid release 
combination, the local concentration of doxorubicin should increase in a progressive 
pattern that is proportional to the liposome concentration. Hence, the tumour is exposed 
to doxorubicin molecules at a sub-lethal concentration throughout the accumulation 
duration (e.g. 24 hours) and this increases the likelihood of the tumour to developing 
drug resistance (Sterpetti et al. 2006).  
 
Compared with EPR based-DDS, DDS designed to be triggered by hyperthermia has the 
advantage of being able to rapidly release most of the encapsulated doxorubicin upon 
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introduction of the required external force. This helps to maximize the local concentration 
of doxorubicin and minimize the likelihood of the tumour being subjected to a sub-lethal 
concentration.  
 
While both liposome and polymeric nanoparticles have been made to be thermal 
sensitive, currently, thermal sensitive liposomes are the only available DDS that can be 
used to rapidly release the encapsulated agent upon heating.   
 
 
2.3.1. Thermal sensitive liposome 
 
With DPPC (1,2-dihexadecanoyl-sn-glycero-3-phosphocholine) as its main lipid 
component, thermal-sensitive liposome (TSL) is a category of liposomes that, on the one 
hand, possess the capacity to release encapsulated drug in response to an increase in 
temperature in a  mild-hyperthermia range, whilst on the other hand, is able to prevent 
premature leakage of encapsulated drug at physiological temperatures (Yatvin et al. 
1978). Based on the mechanism of drug release upon heating and the lipid it contains, 
thermal-sensitive liposome can be further divided into traditional thermal sensitive 
liposome (TTSL) and lysolipid incorporated thermal-sensitive liposome (LTSL) 
(Ickenstein et al. 2003). 
 
2.3.1.1. Traditional thermal sensitive liposome for tumour treatment 
 
Compared to the other type of TSL (i.e. lysolipid-containing thermal sensitive liposome, 
to be discussed later), tradition thermal sensitive liposome (TTSL) vesicles solely utilize 
DPPC as their source of thermal sensitivity, as well as being the main membrane 
component. In general,  the membrane of liposome undergoes solid crystalline, liquid 
crystalline, and an intermediate co-existence phase that contains both phases, at below, 
above, and the phase transition temperature of the lipid membrane, respectively. These 
three membrane states differ from each other in their permeability and other physical 
and chemical characteristics (Mills and Needham. 2005). For TTSL, at physiological 
temperature (37oC), a rigid solid-crystalline phase of liposome, characterized by its tight 
membrane packing, gives the membrane a low permeability, preventing premature 
leakage of encapsulated material (Mills and Needham. 2005). Upon heating, the 
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solidified membrane starts to melt from the grain boundary area of the membrane 
(Ickenstein et al. 2003). As a consequence of molecular mismatch of lipid chains at the 
boundary, a highly compressible interface begins to form, a phenomenon which is 
currently believed to account for an increase in permeability (Winter et al. 2010). The 
total area of the interface reaches its maximum at around 42oC (phase transition 
temperature of TTSL) which is within the temperature range required for the  maximum 
permeability of the membrane (Mills and Needham. 2006). Upon further heating, the 
interfacial area disappears gradually until the formation of a pure liquid phase, 
accompanied by a reduction in permeability (Mills and Needham. 2005).  
 
The first attempt to develop chemotherapy-encapsulated TTSL was reported by Yatvin 
et al (Yatvin et al. 1978): using DPPC and DSPC as membrane components, more than 
50% of encapsulated cisplatin were rapidly released after 3 min heating at 42oC.  After 
further formulation optimization, stealth doxorubicin-encapsulated TTSL composed of 
DPPC, HSPC (hydrogenated soy phosphatidylcholine), cholesterol and PEG.lipid was 
developed (Gaber et al. 1995).  The resultant vesicles were reported to be able to 
release 50% of encapsulated doxorubicin after 30 min heating at 42oC. (Gaber et al. 
1995). Unfortunately, although the group that developed this TTSL system did not carry 
out further in vivo testing, its anti-tumour effect was reported  to be ineffective compared 
with a more advanced LTSL system (Needham.et al. 2000).  This particular publication 
may have played a part in the lack of further development of such  potentially highly 
promising TTSL vesicles, a formulation that until very recently proved to be very effective 
both in vitro and in vivo (de Smet et al. 2013).   
 
2.3.1.2. Lysolipid-containing thermal sensitive liposome (LTSL) for tumour treatment 
 
Different from TTSL, the thermal-sensitivity of LTSL vesicles has been claimed to stem 
from the combined effect of DPPC and lysolipid (a phospholipid that has one rather than 
two lipid chains). Being regarded as impurities, lysolipids are thought to be incorporated 
at the boundary region of the lipid membrane during the preparation of vesicles (Mills 
and Needham 2005). Upon heating which initiates the formation of a solid-liquid 
interface, lysolipids (with a conical molecular shape), at a desirable concentration (a 
concentration between 5-10% is mostly applied), have been reported to create and 
stabilize the hydrophilic water pores along the highly compressible liquid–solid 
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boundaries which significantly enhances the permeability of liposome (Mills and 
Needham. 2005). Among various anticancer agent-encapsulated LTSL vesicles, 
ThermoDox® - a doxorubicin-encapsulated LTSL is considered  the most widely studied 
and successful formulation. Consisting of 10% C-18 lysolipid, 5% PEG.DSPE.2000 
(PEG lipid with a molecular weight of 2000), and 85% DPPC (Poon and Borys. 2009), 
ThermoDox® has been reported to release 100% of the encapsulated doxorubicin within 
30 s (Mills and Needham. 2005). Accompanied with the first in vivo application of 
ThermoDox®, a novel vesicle delivery strategy via intravascular release has been 
developed with the aim to maximize the anti-tumour efficiency of LTSL (Needham.et 
al.2000). 
 
 
 
Figure 2.5. Schematic that demonstrates the main function of ThermaDox
®
. Prior to the 
administration of ThermaDox
®
, the targeted tumour site is heated using external source. 
Encapsulated doxorubicin is then released within blood vessels that feed the tumour 
(Chen et al. 2004). Also shown in the figure is the release mechanism of doxorubicin (i.e. 
released at the solid-liquid boundary of liposome upon heating). 
 
Intravascular release refers to a strategy in which the main site of doxorubicin release 
occurs within blood vessels in the tumour (Chen et al. 2004). Prior to the treatment, the 
tumour region is heated to a designated temperature, once thermal equilibrium is 
established, LTSL is then injected intravenously, aiming to destroy the endothelial and 
tumour cells  located at the perivascular regions. Using water bath as a method of 
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heating, the combinatorial effects of various LTSL and intravascular release strategy 
have been studied intensively and accepted as the method of choice (Chen et al. 2004, 
Mills and Needham. 2005). It offers two major advantages to the patients:  
 The accumulated amount of doxorubicin at the heated tumour area is much 
higher compared to extravascular release (Needham et al. 2000).  
 Released doxorubicin can damage the micro-vessel that nurtures the tumour 
(Chen et al. 2004).  
The first advantage is due to the combined effect of a higher initial plasma vesicle 
concentration and higher permeability of free doxorubicin (Kong et al. 2000). The second 
advantage stems from the release of doxorubicin within the micro-vessel that nurtures 
the tumour, which has been reported to lead to a spontaneous reduction of blood flow in 
affected vessels and a subsequent destruction of endothelial and perivascular tumour 
cells around the affected area (Chen et al. 2004). As heating by water bath cannot be 
applied in vivo, the feasibility of clinically available heating methods (e.g. radiofrequency 
ablation or high intensity focused ultrasound, etc.) has been extensively studied both in 
vitro and vivo, with satisfactory results.    
 
2.3.1.3. Failed clinical trials of LTSL for tumour treatment  
Possibly as a result of impressive ex vivo data (Kong et al. 2000), a stage 3 
ThermoDox®  clinical trial (HEAT trail) was initiated in the US in 2008 to treat liver 
cancer  using radiofrequency ablation (RFT) as the heating source. Unfortunately, it has 
recently been reported that ThermoDox® in combination with RFA did not benefit the 
patients compared to the reference group and failed to reach the goal of the trial. Prior to 
the initiation of such a high profile clinical trial, highly variable effectiveness of 
ThermoDox® intravascular release strategy on various animal tumour models had 
already been reported by the same group (Yarmolenko et al. 2010). In this study, 
variations of blood flow pattern were regarded as the potential causes of failure 
(Yarmolenko et al. 2010), as high blood flow fluctuations in the peripheral region of the 
tumour has been  reported (Durand. 2001). Reduced blood flow may partially block the 
entrance of the affected micro-vessel, making it unavailable for doxorubicin to either 
pass through and enter the tumour or damage the vessel. However, it is possible that 
the widely reported LTSL instability may have played in part in the failure of HEAT trial.  
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As mentioned above, Lysolipids have been claimed to be the crucial component that 
enables LSTL vesicles to release encapsulated substances rapidly upon heating as a 
result of its single hydrocarbon chain structure. Unfortunately, there have been growing 
reports of lysolipid-protein interactions and various groups have linked such undesirable 
phenomena to the widely reported LTSL instability at 37oC (Al-Jamal et al. 2012, Li et al. 
2013). What is more, recent studies have demonstrated the desorption tendency of 
lysolipids from their originally incorporated vesicles upon the presence of liposome-alike 
substance such as red blood cells or other lysolipid-free vesicles at physiological 
temperature  (Sandström et al. 2005, Banno et al. 2010). Using L-α-
phosphatidylcholinecontaining liposomes to mimic red blood cells, ThermoDox®  has 
been reported to have lost 50% of its originally incorporated lysolipid after 10 min 
incubation (Sandström et al. 2005).  Accompanied with such lysolipid desorption is a 
dramatic loss of doxorubicin, with more than 50% loss of the encapsulated doxorubicin 
molecules within 5 min of the addition of red blood cells (Banno et al. 2010).  The above 
in vitro data strongly suggest that there is a possible relation between the desorption of 
lysolipid and inferior in vivo stability of incorporated vesicles.  
  
However, it has to be emphasized here that the extent of doxorubicin leakage from 
LSTLs in vivo has shown considerable variation among publications. Using serum from a 
tumour bearing mouse, more than 50% of the originally encapsulated doxorubicin 
molecules have been found to be lost from LSTL after 1 hour incubation at physiological 
temperature (Al-Jamal et al. 2012). On the other hand, LSTLs incubated in a healthy 
mouse serum is much more stable, with less than 20% loss after 1 hour incubation (Li et 
al. 2013). In addition, LSTLs have shown different sensitivities to serum from different 
animal species and it has been reported that mouse serum results in the highest level of 
doxorubicin leakage, while LSTL is least susceptible to calf serum (Hossann et al. 2012).   
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2.3.2. Polymer-based thermal sensitive nanoparticles  
 
While liposome may be the first nanoparticle system that has been shown to be a 
suitable drug carrier for heat activated release of encapsulated material, the usage of 
thermal sensitive polymers has a long history in industry (Schild. 1992), mainly as 
surfactant or viscosity modifier. Poly-N-isopropylacrylamide, (PNIPAM, show in Figure 
2.6) - the first synthesized thermal sensitive material, is a polymer that has a unique 
solubility characteristic; its solubility reduces upon temperature rise, a property contrary 
to the behaviour of most polymers (Schild. 1992). The temperature at which such a 
transition occurs is called the lower critical solution temperature (LCST); below the 
LCST, the polymer is in its extended form and remains soluble in aqueous media. Once 
temperature exceeds LCST, it becomes hydrophobic and shrinks (precipitates) in water 
(Kohori et al. 1999).  
 
 
 
Figure.2.6. Molecular structure of PIPAAM, the first thermal sensitive material.  
 
As the LCST of PIPAAM (34OC) is close to the physiological temperature of human 
body, it should be a good candidate as a thermal responsive material. The major 
weakness of PIPAAM, however, is the lack of an ideal structure that offers a desirable 
LCST (> 400C) and rapid release behaviour. In the late 90s, the team behind the 
development of polymeric nanoparticles composed of doxorubicin-conjugate developed 
a PNIPAM-based micelle with doxorubicin being encapsulated in the interior of micelle 
(Kohori  et al. 1999). While the resultant product offers a desirable LCST (400C), the 
slow release behaviour makes it difficult to be used as a thermal sensitive doxorubicin 
carrier for drug delivery (Kohori  et al. 1999 ).  
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2.4. Tissue plasminogen activator-encapsulated TSL for thrombolysis 
 
Compared with the long historical background of cancer-targeting DDS, the development 
of DDS for tPA delivery did not start until the 2000s and is still much less developed than 
for cancer-treating DDS. In chronological order, 4 types of tPA-incorporated DDS have 
been developed:  
 tPA-covalently conjugated carrier in 2003 (Murciano et al. 2003) 
 Ultrasound sensitive tPA-liposome complex in 2007 (Tiukinhoy-Laing et al. 2007) 
 Magnetic guided ultrasound responsive polymer tPA DDS in 2008 (Kaminski et al. 
2008) 
 Shear-activated tPA-conjugated nanotherapeutics  in 2012 (Korin et al. 2012) 
 
2.4.1. Development of tPA-covalently conjugated carrier  
 
As has been stated in the introduction, patients that receive a pure tPA infusion have a 
high risk of experiencing undesirable side effects as a result of undesirable 
pharmacokinetic behaviour of the protein (e.g. high adherence to tissue and haemostatic 
blood clots, etc). Aiming to prevent such unwanted penetration of free tPA molecules 
into haemostatic fibrin and to increase the half-life, tPA molecules have been covalently 
conjugated with nano- or micro- sized carriers. Among various formulations that follow 
such a strategy, tPA-conjugated red blood cells (i.e. tPA/RBC) is one of the most well-
known and studied delivery system. Thanks to the micron-size of red blood cells and the 
strong bond between tPA molecules and the carrier, the half-life of tPA/RBC has been 
dramatically enhanced compared to pure tPA infusion and the other tPA-conjugated 
vesicle systems (Ganguly et al. 2005). In addition, compared with free tPA molecules,  
tPA/RBC have lower affinity to haemostatic fibrin, thereby reducing the risk of internal 
bleeding (Ganguly et al. 2005). The core mechanism of tPA/RBC is illustrated in Figure 
2.7. 
 
Ironically, the thrombolytic efficiency of tPA/RBC also suffers as a result of its large 
particle size. Due to the higher drag force it may experience under blood flow 
(proportional to the radius of the particle), the micron-sized tPA/RBC is  less likely to 
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accumulate onto the targeted blood clot compared with free tPA molecules (Korin et al. 
2012).  
 
 
Figure. 2.7. Schematic that demonstrates the concept of  tPA/RBC (adopted from Murciano 
et al. 2003).  The main function of tPA/RBC is to dissolve the newly formed blood clot in 
circulation without damaging the already formed blood clot. Surprisingly,  tPA/RBC is also 
proved to be useful to lysis blood clot that causes embolism.   
 
   
 
2.4.2. Ultrasound sensitive tPA-liposome complex 
 
Echogenic tPA associated liposomes (tPA-ELIP) were initially designed to enable 
liposomes to release encapsulated tPA using low intensity ultrasound as a trigger source 
(i.e. diagnostic ultrasound) (Tiukinhoy-Laing et al. 2007). Air bubbles are co-
encapsulated into the liposome as an ultrasound contrast enhance agent (Huang et al. 
2001), while a certain percentage of tPA molecules are associated with the liposome 
membrane to grant the liposome blood clot-targeting capability (Tiukinhoy-Laing et al. 
2007). Both in vivo and in vitro, tPA-ELIPs have been shown to be able to accumulate at 
the blood clot site and release the encapsulated tPA molecules by ultrasound. 
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However, an anionic lipid has been used in the formulation to increase the “apparent tPA 
encapsulation”. As a result, only a small proportion of tPA molecules (around 15%) is 
truly encapsulated in the interior of the liposome, with the rest being either loosely 
associated with, or incorporated into the liposome membrane (Smith et al.2010). This 
deviates from the initial concept of tPA-ELIP (i.e. to locally “release” tPA molecules by 
ultrasound). As a result, it may be reasonable to speculate that, rather than burst release 
of encapsulated tPA at the blood clot site, the observed superior thrombolytic rate 
enhancement was merely a combined effect of improved pharmacokinetic profile of tPA-
ELIP (i.e. longer t1/2 and blood clot target capability) and enhanced tPA efficiency against 
blood clots under ultrasound exposure (Everbach et al. 2000).  
 
 
2.4.3. Magnetic guided  ultrasound responsive polymer tPA DDS 
 
Diagnostic ultrasound (i.e. low-intensity ultrasound with high duty cycle) is used in 
magnetic guided ultrasound responsive polymer tPA DDS to release the incorporated rt-
PA through the degradation of polymer in response to acoustic power (Kaminski et al. 
2008). The latest progress in this area involves the establishment of a magnetic-guided 
and tPA incorporated PEG-PLA microsphere (Kaminski et al. 2008). Although in vitro 
experiments demonstrate the release of tPA triggered by ultrasound, the rate of tPA 
release is not satisfactory (took more than 1 hour for complete release, Kaminski et al. 
2008).   
 
2.4.4. Shear-activated  tPA-conjugated nano-therapeutics  
 
Shear-activated tPA-conjugated nano-therapeutics (tPA-Ns) is an amazing design that 
utilizes the shear-stress sensitivity of its fabricated micro-particle counterpart. PLGA 
nanoparticles are initially fabricated into micro-aggregates by a spray-drying technique; 
tPA-molecules are then coated onto the aggregates through covalent bonding (Korin et 
al. 2012).  Upon injection, the micro-particles spontaneously break up into tPA-
conjugated nanoparticles at the blood clot site due to the high shear stress of the local 
environment.  The combined effect of smaller particle size of tPA-NS and high surface 
exposure of tPA molecules grants the nanoparticle high blood clot adherence 
functionality (Korin et al. 2012).  In addition, since the surface area is much smaller than 
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a single micro-particle aggregate, the majority of tPA molecules will not be exposed to 
haemostatic blood clot, making it an even safer and blood clot specific formulation in 
comparison to the existing tPA-liposome counterparts. The concept of shear-activated 
tPA-Ns aggregates is illustrated in Figure.2.8. 
 
 
Figure 2.8. Schematic that demonstrates the concept of shear-activated tPA-Ns aggregates 
(adapted from Korin et al. 2012).  Micro-particle is broken into nanoparticles when passing 
through the blood clot.   
 
Its major shortcoming lies in its inability to lysis blood clots that totally block the vessel, a 
circumstance that is commonly encountered in patients. As a high shear-stress tunnel is 
needed to break up tPA-Ns aggregates, a total blockage of a vessel will prohibit the 
transformation of micro-particles into tPA-Ns.     
 
2.5.Summary 
 
As the cytotoxicity of doxorubicin is proportional to its local concentration, the most 
desirable doxorubicin-DDS is to maximize the concentration of free doxorubicin in 
tumour within a short period of time, whilst limiting doxorubicin exposure to normal 
enzymes or cells. Currently, EPR-based nanoparticles and LTSL are two main types of 
DDS that aim to achieve these desirable features. However, the current generation of 
EPR-based doxorubicin-DDS may stimulate the acquirement of multidrug resistance due 
to its long accumulation time (Al-jamal et al. 2012, Sterpetti et al. 2006). Compared with 
EPR-based doxorubicin-DDSs, LTSL has advantage over the other systems as it is able 
to release most of the encapsulated doxorubicin at desirable area within a short 
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treatment time (Needham et al. 2000), reducing the chance of multidrug resistance 
development.  However, the presence of lysolipids reduces the stability of LTSL in 
circulation, resulting in premature leakage of doxorubicin at physiological temperature 
(Al-jamal et al. 2012).    
 
Similar to doxorubicin, the extent of blood clot lysis is proportional to the local 
concentration of tPA. Hence, the ideal DDS for tPA should have a similar pattern as its 
doxorubicin counterpart (i.e. rapidly release tPA at targeted blood clot within a short 
period of time, whilst limiting tPA availability in circulation). Currently, tPA-ELIP and tPA-
Ns are two types of DDSs that are designed to meet these requirements. While tPA-
ELIP has a long history of development (Tiukinhoy-Laing et al. 2007, Laing, et al. 2012), 
only a small population of tPA is shielded from circulation environment and this reduces 
the selective targeting nature of DDS toward desirable pathological blood clot. Currently 
tPA-Ns is the only tPA-DDS that is able to selectively release majority of tPA molecules 
at pathological blood clot area (Korin et al. 2012).  However, the presence of high shear 
stress is the pre-condition of tPA release (Korin et al. 2012). As a result, such DDS may 
not be able to unblock vessel that is totally blocked, which is common in patients 
suffering from acute ischemia stroke. Other types of tPA DDS either lack the ability to 
selectively target pathological blood clot (RBC/tPA) or have insufficient tPA release rate 
(magnetic guided ultrasound responsive polymer tPA DDS).  
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Chapter 3. Development of simple and stable 
thermal sensitive liposomes for the 
treatment of solid tumour  
 
 
3.1. Introduction  
 
TTSL composed of DPPC: HSPC cholesterol and DSPE.2000 has been reported to 
have much lower thermal sensitivity and anti-tumour effect compared with lysolipid 
containing TSL (Needham et al. 2000). However, a recent study by De Smet et al  on the 
once neglected TTSL formulation demonstrated it as a worthy liposomal carrier of 
doxorubicin (De Smet et al. 2011). The TTSL prepared by this group was found to 
rapidly release  90% of the encapsulated doxorubicin  after 5 min heating at 42oC (De 
Smet et al. 2011, 2013).However, while its anti-tumour efficiency is yet to be determined, 
the combination of intravascular release and their TTSL vesicles led to a significantly 
lower release of doxorubicin in the tumour area compared with LSTL (Al-Jamal et al. 
2012).  As a result, whether TTSL of this type can be used as an alternative to the 
currently unstable LSTL for tumour treatment is still unknown. As sterically stabilized 
DPPC liposomes have been shown to be able to rapidly release the encapsulated 
molecules (Woo et al. 2008), one of the aims of the project is to determine whether it is 
feasible to utilize simple doxorubicin-encapsulated TSL composed solely of DPPC and 
PEG.lipid (PEG2000.DSPE) at 96:4 molar ratio to replace the current LTSL vesicles. In 
order to simplify the terminology used in the thesis, TSL in the following text only refers 
to vesicles composed solely of DPPC and PEG2000.DSPE.   
 
As mentioned in section 1.6, encapsulating a higher amount of doxorubicin is a desirable 
property liposomal doxorubicin: As long as the presence of doxorubicin molecules does 
not compromise the integrity of liposome membrane, a higher amount of encapsulated 
doxorubicin per lipid (drug to lipid ratio D/L, W/W) can help reduce the % leakage of 
encapsulated doxorubicin at physiological temperature and increase the amount of 
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doxorubicin that is available for tumor deposition (Jonhnston et al. 2008). However, 
thermal sensitive liposomes (including TSL) often have a much lower D/L ratio compared 
with their non-thermal sensitive counterparts (Chiu et al. 2005). As demonstrated in the 
table 3.1, the D/L ratio of thermal sensitive liposome (~0.05) is usually 5 times lower than 
the D/L ratio of non-thermal sensitive liposome (~0.3). In the current project, effort has 
also been made to increase the doxorubicin loading capacity of TSL.  
 
Table 3.1. Summary of reported D/L ratio of liposomal doxorubicin in the literature 
Type of formulation 
 
Composition of formulation (mole 
ratio ) 
 
Dox/lipid  ratio 
(W/W) 
Reference 
DPPC-based thermal  
sensitive liposome 
 
 
DPPC:DSPE.PEG.2000 
(100:4) 
0.05 
 
Banno et al. 
2010 
 
DPPC: MSPC: DSPE- 
PEG2000 
(90:10: 4) 
0.05 
 
Banno et al. 
2010 
 
DPPC/DSPC/ DSPE-PEG2000  
(90:10:5) 
 
0.05 
 
Al-Ahmady et al. 
2012 
 
DPPC:HSPC: 
Chol:DPPE. PEG2000 
(50:25:15:3) 
 
0.06 
de Smet et al. 
2011 
Non-thermal sensitive 
liposome 
EPC:chol 
(7:3) 
0.33 Fritze et al. 2006 
DSPC: chol 
(7:3) 
0.39 
Johnston et al. 
2008 
 
DPPC represents 1,2-dipalmitoyl-sn-glycero-3-phosphocholine. DSPE.PEG.2000 represents 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000. MSPC 
represents 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine. DSPC represents 1,2-distearoyl-
sn-glycero-3-phosphocholine. EPC represents egg phosphotidylcholine. Chol represents 
cholesterol.  
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3.2. Selection of preparation method for doxorubicin-encapsulated vesicle  
 
Up until now, the pH gradient method has been the most widely adopted procedure to 
achieve a high loading of doxorubicin  in liposomal vesicles. Therefore this active loading 
strategy was selected as the liposome preparation method in this project. In general, the 
preparation of liposomal doxorubicin large unilamilar vesicles (LUV) consists of the 
following three steps:  
1) Prepare multilamilar liposome vesicles (MLV) and subsequently LUV.   
2) Create cross-membrane pH gradient.  
3) Incubate pH gradient-established LUV into doxorubicin-containing solution 
(incubation step).  
 
Proper handling of the first step will not only influence some of the crucial characteristics 
of the liposome membrane (e.g. phase transition temperature, component of lipid, etc) 
but also determine the total amount of lipid that is available for doxorubicin 
encapsulation.  While successful execution of the rest two steps (pH gradient active 
loading of doxorubicin) will greatly affect the eventual drug to lipid ratio (D/L) of 
liposomes.   
      
3.2.1. Preparation of multilamilar and large unilamilar liposome and optimization of 
preparation process 
 
Preparation of dried lipid film followed by hydration is regarded as one of the most 
commonly used methods for the preparation of MLV containing mixed lipids.  At first,  
lipid organic solutions are mixed at a desired percentage.  Solvent is removed using a 
rotorary evaporator under vacuum to form a dried thin layer. Subsequent hydration of 
dried lipid film is then carried out using selected buffer (Walde et al. 2001). Due to the 
amphiphilic characteristics of phospholipids, MLVs are formed with a particle size 
ranging from 0.5 to 10 µm (Olson, F et al. 1979). Extrusion is then carried out to reduce 
the size of the vesicles.  
 
Extrusion of liposome is a technique by which MLVs are forced to pass through a filter 
with a defined pore size to yield liposome particles with diameters close to the pore size 
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of the filter used.  It has been reported that breaking and resealing of the MLV 
membrane can occur when vesicles are trying to pass through the pores, forming large 
LUV (Hope et al. 1993).  In order to obtain a homogenous LUV population, a 10-cycle 
extrusion operation is usually recommended (Hope et al. 1993).  
 
As written in the extrusion handbook provided by the extruder manufacturer (Avanti 
Polar Lipids Inc. Alabaster, AL, USA), the temperature used during extrusion needs to 
be higher than the phase transition temperature (Tm ) of vesicle membrane and failing to 
do so will not only result in a significant loss of lipid during extrusion, but also increase 
the force needed for the lipids to get through the membrane. Therefore, in the present 
study, the temperature during extrusion was carefully controlled and ensured to be 
above Tm to minimize the lipid loss during extrusion process.  
 
3.2.2. pH gradient active loading of doxorubicin 
 
A schematic that illustrates the general process of pH active loading of doxorubicin is 
shown in Figure 3.1. In general, the method utilizes the difference in membrane 
permeability between protonated and depronated forms of doxorubicin (Cullis et al. 
1991):  prior to the initiation of doxorubicin encapsulation process, a stable cross-
membrane pH gradient of 3 is required to be formed by hydrating ddruried lipid film using 
an acidic (pH =4) phosphate buffer, followed by  exchanging the exterior buffer with a 
basic buffer (pH =7).  After the completion of buffer exchange, encapsulation of 
doxorubicin is initiated by introducing doxorubicin into the LUVs solution (incubation 
step). Having an acid dissociation constant (pKa) of 8.13, doxorubicin molecules should 
be in their depronated and protonated form in basic and acidic environment, respectively 
(Fritze et al. 2006).  Due to the higher permeability of deprotonated doxorubicin in the 
exterior basic environment, doxorubicin is able to pass through the membrane; 
subsequent protonation of doxorubicin in the acidic interior environment, on the other 
hand, will prevent the movement of doxorubicin from going out (Harrigan et al. 1993). It 
is the combined result of continuous inward movement of depronated doxorubicin and 
caging of protonated doxorubicin within the acidic vesicle interior that leads to the 
encapsulation of doxorubicin with a high D/L ratio.  
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During experimental designing, the selection of hydration buffer (i.e. acidity of buffer and 
valancy of the counterion) is crucial as it contributes strongly to the final l D/L of the 
resultant doxorubicin-TSL. This will be discussed in detailed below.    
 
 
Figure 3.1. Schematic of pH gradient method for doxorubicin encapsulation. During pH 
exchange step, crosee-membrane pH gradient is established. Incubation step is the crucial 
step during which doxorubicin molecules pass through the membrane, whereas the 
previously established pH gradient remains relatively intact.   
 
 
3.2.2.1. Early development of pH gradient method   
 
As illustrated in Figure 3.1, the establishment of a cross-membrane pH gradient not only 
regulates the distribution of protonated and deprotonated doxorubicin, but also results in 
the formation of “deprotonated doxorubicin gradient”, increasing the D/L of doxorubicin 
by catalyzing the inward movement of depronated doxorubicin molecules. Hence, in 
order to maintain the “deprotonated doxorubicin gradient” and high D/L ratio, the cross-
membrane pH gradient needs to be maintained throughout the encapsulation process.  
 
During the early development and optimization of pH active loading, vesicles composed 
of egg phosphatidylcholine (EPC) and cholesterol were utilized and it was found that 
such vesicles were unable to sustain their original pH gradient.  Unlike most ion 
molecules, the permeability of small hydrogen protons through membranes composed of 
EPC and cholesterol is extremely high (Cullis et al. 1991). In response to an already 
established pH gradient (i.e. an H+ proton gradient), protons have strong outward-
membrane tendency in order to establish an electro-chemical gradient (Cullis et al. 
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1991). Hence, a cross-membrane pH gradient may have been compromised even prior 
to the initiation of doxorubicin encapsulation. Such a proton depletion state is further 
accelerated during the doxorubicin encapsulation process as the basic nature of 
doxorubicin molecules further consumes protons. Hence, in order to compensate for the 
potential loss of protons during the liposomal preparation process, early effort on pH 
gradient optimization focused on maximizing protons by increasing the concentration 
and  acidity of the buffer (Harrigan et al. 1993).  
 
In parallel, an ammonium buffer gradient loading was proposed as an alternative version 
of pH gradient loading strategy (Haran et al. 1993, Fritze et al. 2006, Mayer et al. 1994). 
Using EPC/cholesterol vesicle as model vesicles and a basic ammonium buffer (e.g. 
ammonium phosphate) as the hydration buffer, a cross membrane ammonium buffer 
gradient can be established initially after the removal of exterior ammonium buffer. This 
induces the outward movement of encapsulated ammonium molecules (NH3) that 
equilibrates with protonated ammonium buffer (e.g. NH4SO4), leaving the relatively 
impermeable protons (i.e. H+) within the vesicle interior (Mayer et al. 1994). As a result, 
a pH gradient is spontaneously formed. A simplified schematic that illustrates the 
principle of ammonium buffer gradient is given in Figure 3.2, using ammonium 
phosphate as an example.  It was later suggested that a combined utilization of the 
ammonium and pH gradient (i.e. high interior ammonium concentration and low pH vale) 
would maximize the proton population and increase the D/L ratio of doxorubicin (Fritze et 
al. 2006), although experimental data were lacking. The loading strategy developed for 
EPC/cholesterol vesicle, however, cannot be directly applied to maximize the D/L ratio of 
DPPC: PEG.2000.DSPE vesicles as the behaviour of the two membrane systems during 
liposomal doxorubicin preparation is fundamentally different.  
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Figure 3.2. Brief description of ammonium gradient method for doxorubicin encapsulation. 
Ammonium phosphate is used as an example buffer.  
 
 
 
3.2.2.2. Selection of acidic buffer for DPPC-based vesicle system for optimal D/L ratio of 
doxorubicin  
 
Unlike vesicles composed of EPC/cholesterol, the transmembrane movement of H+ in 
DPPC vesicles is heavily restricted at room temperature (Chiu et al. 2005). As a result, 
prior to the initiation of doxorubicin encapsulation, the established pH gradient is unlikely 
to experience  depletion.  Hence, an acidic buffer without the addition of an ammonium 
gradient has been frequently used to prepare doxorubicin-TSL systems (Banno et al. 
2010, Chiu et al. 2005, Dos Santos et al. 2004). However, as the H+ due to doxorubicin 
accumulation still occurs during encapsulation process, maximization of H+ through a 
combination of pH and ammonium gradients is still a preferred strategy. Hence, in this 
project, an acidic ammonium buffer was selected as the interior buffer to increase the 
potential D/L ratio of doxorubicin. The selection of counter ion of interior buffer (e.g. 
critic, phosphate, etc) will be discussed later. 
 
 
3.2.2.3. Selection of counterion and its effect on the morphology of liposomal 
doxorubicin  
 
Although an acidic environment of vesicles is able to restrict cross-membrane movement 
of protonated doxorubicin molecules, satisfactory vesicle stability cannot be achieved 
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simply by regulation and maintenance of an established pH gradient.  Since the 
development of pH gradient method, it has been later discovered that the presence of 
multivalent counterions (e.g. citrate, sulfate and phosphate) in the buffer plays an 
unexpected but significant part in enhancing vesicle stability by encouraging the 
formation of stable doxorubicin crystals under acidic conditions: Doxorubicin molecules 
in the presence of a multivalent counterion  containing buffer have been reported, using 
SEM and X-ray diffraction, to be in the form of bundles of fibres that longitudinally align 
in a hexagonal array even at very low concentrations (<34 μM) (Li et al. 1998). 
Depending on the valency of the counterion and the acidity of the buffer, doxorubicin is 
expected to experience two stages of crystallization.  
 
The first stage of crystallization involves the formation of doxorubicin fibres and is the 
result of the lyotropic behaviour brought by counterions under acidic condition, 
irrespective of the valency of the counterion.  As a result of their lyotropic behaviour (i.e. 
the ability of ion to withdraw water from amphiphilic molecules), the presence of 
concentrated counterions decreases the solubility of doxorubicin by removing its 
hydration shell (Fritze et al, 2006), resulting in the stacking movement (i.e. formation of 
fibres) of doxorubicin molecules (Li et al. 1998). As the amphiphilic nature of doxorubicin 
molecules is a pre-condition of precipitation, the maintenance of buffer acidity throughout 
the process is crucial for doxorubicin precipitation.      
 
The formation of a bundle of doxorubicin fibres is the second step of counterion-induced 
doxorubicin crystallization. In addition to the acidity of buffer, the morphology of 
doxorubicin crystal depends strongly on the valency of the selected counterion:  acting 
as an electrostatic bridging force, multivalent counterions are able to bridge two 
protonated doxorubicin molecules (under acidic condition) on two adjacent fibres (Li et 
al. 1998). This eventually leads to the formation of doxorubicin bundles that are 
composed of fibers (i.e. the product of first level of precipitation) that longitudinally align 
in a hexagonal array (Li et al. 1998). If the buffer only contains mono rather than 
multivalent counterions (e.g. lactobionic acid), the counterion molecules are unable to 
connect two separate doxorubicin fibres and unable to form bundles (Li et al. 1998).  
Similar to the formation of doxorubicin fibers, the acidity of buffer needs to be maintained 
as it ensures the protonation of doxorubicin, which is the precondition of electrostatic 
force-based connection.  
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3.2.2.4. Final determination of interior buffer   
 
In order to achieve a high D/L ratio of doxorubicin, an acidic ammonium buffer using 
phosphate as counterion was selected as the hydration buffer. The addition of an 
ammonium gradient was expected to increase the population of H+ protons, increasing 
the D/L ratio of doxorubicin and fulfilling the pre-condition of doxorubicin crystallization. 
No preference was made regarding the selection of counterion and phosphate ion was 
selected due to its availability in the lab.  
 
3.3. Selection of method to determine encapsulation efficiency of liposome  
 
The encapsulation efficiency of liposome prepared in the project was illustrated by the 
amount of doxorubicin encapsulated in the liposome divided by the amount of lipid 
(drug/lipid ratio, w/w).  The total amount of lipids was determined using Stewart assay 
and the amount of doxorubicin was determined using the same self-quenching 
mechanism mentioned in section 3.3. 2. 
 
The Stewart assay is a classic biphasic colorimetric phospholipids determination method 
that utilizes the ability of phospholipids to form a complex with ammonium 
ferrothiocyanate (Stewart. 1980). Following a simple extraction procedure, the 
concentration of phospholipids in chloroform phase was determined from the optical 
intensity at 480 nm wavelength (Stewart. 1980). 
 
The amount of doxorubicin encapsulated was obtained by comparing the fluorescence 
intensity difference prior to and after total destruction of liposome through the addition of 
detergent (triton X-100) using the equation 4.  The extent of liposome destruction upon 
triton addition was monitored by the changes of particle size prior to and after the 
addition of triton X-100.   
 
𝐹𝑓𝑢𝑙𝑙 − 𝐹0                                                              <4> 
where F0 is the amount of encapsulated material detected prior to heating, , Ffull  is the 
total amount of doxorubicin detected after complete release of doxorubicin using 1 v/v % 
Triton X-100. 
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3.4. Preparation and analytical process of doxorubicin-TSL 
 
This section describes in detail the preparation and analytical process for nano-sized 
TSL encapsulated with doxorubicin.  
 
3.4.1. Preparation of doxorubicin-encapsulate liposome 
 
Blank LTSL vesicles  (DPPC, MSPC and PEG.DSPE.2000 at a 90:10:4 molar ratio) and 
a TSL vesicles  (DPPC and PEG.DSPE.2000 at 96:4 molar ratio) were prepared using 
lipid film hydration followed by extrusion (Li et al. 2010). In brief, stock lipid chloroform 
solutions, with a total of 5 mg lipid were mixed and solvent was then removed using a 
rotary evaporator to form a dried thin layer. Dried lipid film was hydrated using acidic 
buffer (300 mM ammonium phosphate, pH 4) at 50oC. Liposome solution was then 
extruded through a 100 nm filter from MLV to reduce the size of the liposomes at the 
same temperature. A cross-membrane pH gradient was then established by passing the 
liposome through a Sephadex G-25-packed column (0.8 cm × 10 cm) using HEPES 
buffer as an eluent. Stock doxorubicin solution was mixed with the vesicles and allowed 
to incubate at pre-determined temperature for 1 hour. Liposomes were then separated 
from any unencapsulated doxorubicin on a Sephadex G-20 column using HEPES buffer 
as eluent (0.8 cm × 10 cm).  
 
 
3.4.2. Determination of D/L ratio of liposome 
 
Lipid was quantified using stewart assay. Stock ammonium ferrothiocynate solution was 
prepared by adding 27.03 g of ferric chloride hexahydrate and 30.4 g of ammonium 
thiocyanate into 1L of deionized water. Liposome solution (30µl) was added into 5 ml of 
chloroform solution contained in 15 ml plastic centrifuge tube and was vortexed for 30 
seconds. 5 ml of stock ammonium ferrothiocyanate solution was added into chloroform 
solution and the mixture was vortexed for another 30 seconds. Mixture was then allowed 
to settle for 12 overnight. Chloroform layer was extracted and its UV/Vis absorbance at 
485 nm was determined. When determining the D/L changes of dox-TSL at various 
incubation temperature, 300µl of liposome solution was added into chloroform rather 
than 30µl.  
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Doxorubicin was quantified utilizing its self-quenching characteristic:   20 µl of liposome 
solution was added into 1ml of HEPES buffer. The amount of encapsulated doxorubicin 
was calculated by comparing the fluorescence intensities (emission wavelength 480 nm 
excitation wavelength 555 nm) of sample prior to and after the addition of 1 v/v % Triton 
X100, using equation 4.  When determining the D/L changes of dox-TSL at various 
temperature (figure 4.2), 200 µl of liposome solution was added into 800 µl of HEPES 
and its fluorescence intensities prior to and after the addition after triton was used to 
determine the amount of doxorubicin.  
 
 
 
 
3.5. Results and discussion  
3.5.1. Influence of incubation temperature on the D/L ratio of dox-TSL 
 
When preparing liposomal doxorubicin using pH gradient method, incubation step is a 
crucial process (detailed in section 3.2.2) at which deprotonated doxorubicin molecules 
need to gain access to the interior of liposome, whereas the cross-membrane movement 
of protons (i.e. H+) is still heavily restricted.  In other words, in order to achieve high D/L 
ratio of the resultant liposomal doxorubicin, membrane of liposome need to have 
selectively high permeability to neutral molecules (i.e. neutral doxorubicin molecules) 
during the incubation process.  As temperature is critical to the permeability of liposome 
membrane, the temperature during incubation step (i.e. incubation temperature) needs 
to specially selected according to the phase transition temperature (Tm) of liposome 
membrane. As a rule of thumb, incubation temperature was usually higher than the Tm of 
liposome membrane (Haran et al. 1993, Mayer et al. 1994, Working et al. 1994). 
However, in the case of liposome system that uses DPPC as its main component, the 
selection of incubation temperature has been proved to be difficult:  On one hand, little 
doxorubicin was able to cross though the DPPC membrane in gel phase (~25 oC) (Dos 
Santos et al. 2004). On the other hand, using temperature that exceeds Tm caused 
premature leakage of H+ ion, resulting in depletion of pH gradient (Chiu et al. 2005).  
Consequently,  37oC (sub-Tm of DPPC membrane) has been mostly used as a practical 
incubation temperature in various groups during the preparation of liposomal doxorubicin 
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that use DPPC as main membrane component (Al-Jamal et al. 2012, Banno et al. 2010, 
Hossann et al.2010. Mills and Needham. 2005. Tagami et al. 2011).  
 
With an intention to increase the D/L ratio of dox-TSLs, the influence of incubation 
temperature on D/L ratio of the resultant dox-TSL was studied. In addition, it was hoped 
that such study may provide information regarding the selective permeability changes of 
DPPC-based membrane to neutral molecule at 37 oC. The influence of incubation 
temperature on D/L ratio of the resultant dox-TSLs within 30-36 oC (1 hour incubation 
time) was determined and the results are shown  in Figure 3.3. It is clear that D/L ratio of 
dox-TSLs increased with increasing incubation temperature within the range of  30-36 
oC.  At 30 oC, little doxorubicin could be encapsulated into the liposome. Once incubation 
temperature reached 32 oC, D/L ratio of dox-TSL increased to 0.018. Increasing the 
incubation temperature by another 2 oC further improved the D/L ratio to 0.048. Greater 
improvement in D/L ratio occurred within 34-36 oC, where the D/L ratio of dox-TSLs 
jumped from 0.048 to 0.12.   
 
Figure 3.3. Influence of incubation temperature on D/L ratio of dox-TSLs (n=3). Incubation 
process lasted for 1 hour.  
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Compared with TSLs prepared by other groups (to be detailed in table 4.2), it is clearly 
demonstrated that an optimized incubation process (36 oC for 1 hour) significantly 
increased the amount of doxorubicin encapsulated in the TSL vesicles, increasing the 
D/L ratio of dox-TSLs from normally reported 0.05 to 0.123 (doxorubicin/ lipid w/w). On 
the other hand,  D/L ratio of dox-TSLs prepared in the current project is still significantly 
lower than the D/L ratio of non-thermal sensitive liposome (~0.33).  Given the short 
incubation time during current incubation process (1 hour), it is possible that extending 
the incubation time might further increase D/L ratio of dox-TSLs.   
 
3.5.2. Potential mechanism of selective permeability change of TSL membrane with 
temperature 
 
According to the result demonstrated in figure 3.3, it is demonstrated that the TSL 
membrane was almost impermeable to neutral doxorubicin (i.e. unprotonated 
doxorubicin) at 30 oC. Within the range of 30-34 oC, TSL membrane became 
progressively more permeable to neutral doxorubicin molecules and its permeability 
drastically increased at 34-36 oC. The observed change in permeability coincided with 
the occurrence of ripple-phase of DPPC membrane reported by Xiang et al (Xiang et al. 
1998), who found that ripple-phase of DPPC membrane started to occur at ~32 oC and 
finished at ~36 oC. Similar phase transition behaviour was also reported by another 
group (Heimburg et al. 1998). In addition, the observed permeability change of TSL to 
neutralized doxorubicin is also consistent with the permeability change of DPPC 
membrane to neutralized acetic acid within a temperature range of 30-35 oC (Xiang et al. 
1997). As shown in Figure 3.4, the permeability coefficient of neutralized acetic acid 
progressively increased from 1.7x10-5  to 7.8x10-5 cm/s within temperature range of 25-
34 oC.  When temperature increased to 35 oC, the permeability coefficient of neutralized 
acetic acid significantly increased and reached 20x10-5  cm/s (Xiang et al. 1997).  
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Figure 3.4. Permeability changes of DPPC membrane to unprotonated acetic acid 
molecules within temperature range of 25 to 35 
o
C. The Graph was reconstructed using the 
data reported by Xiang et al. 1997.   
 
 
On the other hand, dithionte ion, a protonated molecule with a much smaller molecular 
weight than doxorubicin has been determined to be unable to cross TSL membrane after 
1 hour incubation at 37 oC (Mills and Needham. 2005). As a result it was speculated that 
the transmembrane pH and buffer gradient were largely retained within this temperature 
range (i.e. 30-36oC). As the occurrence of ripple phase is currently the only observable 
membrane behaviour change of DPPC-based liposome within 30-36oC  (Heimburg. 
1998,  Matsuki, et al. 2005, Needham et al. 2000, Pili et al. 2009, Shibata et al. 2001, 
Wu et al. 2011, Xiang et al. 1997 ), it is likely that during the permeability enhancement 
process, the unique property of ripple phase results in the lifting of rate-limiting hurdle of 
unionized doxorubicin molecules, whereas the obstacle that restricts the cross-
membrane movement of ionized molecules remains largely intact. However, the actual 
property of ripple phase of sterically protected LUV is still without consensus.    
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3.5.2.1. Unsynchronized movement of phospholipid in ripple phase  
 
For some types of lipid such as phosphatidylcholines (e.g. DPPC), the melting of the 
lipid membrane has been considered to take two rather than one steps: Prior to the 
occurrence of phase transition (i.e. from solid to liquid phase), a meta-phase termed 
ripple phase (Pβ), characterized by periodic one-dimensional undulation on the surface 
of the lipid bilayer is formed (Janiak  et al. 1979), as  illustrated in Figure 3.5.  
 
 
 
Figure 3.5. Demonstration of various stages of lipid membrane upon temperature rise (Vist 
and Davis. 1990).  
 
Since the occurrence of ripple phase has been linked to the analgesic effect of human 
membrane, the Pβ has been under considerable investigation.  While the preparation 
method and structure of vesicles account for the occurrence of Pβ (Heimburg et al. 
2000), the environment (e.g. salt concentration, pH etc) has also proved to be crucial to 
the states of ripple phase (Bartucci et al. 1990). In addition, during early studies of Pβ, 
the unsynchronized movement of lipid within the membrane has been detected using 
various techniques. Using X-ray diffraction and DSC, the packing of lipid during Pβ of 
MLV vesicles composed of DPPC was found to be largely unchanged compared with the 
solid-state, whereas the long-axis rotational rate of hydrocarbon chain however was 
markedly increased (Lewis and McElhaney. 2011). More recently, using temperature 
controlled infrared spectrometer, the mobility of different positions of the phospholipids at 
Pβ has been determined by Wu et al (Wu et al. 2011): Upon the transformation of 
membrane from the gel phase to Pβ, the loosening of hydrogen bond structure at C=O 
interfacial area has been found to be the noticeable variation, whereas the lipid tail 
packing state has barely changed (Wu et al. 2011). Three positions of lipid and 
membrane are illustrated in figure 3.6.  
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Figure 3.6. Demonstration of C=O (carbon and oxygen double bond) in the DPPC 
molecules. This chemical structure is the component that forms the interfacial area of the 
membrane, as shown on the left.  
 
It is likely that the temperature at which the loosening of hydrogen bond network at the 
interfacial area was initiated coincided with the starting point of permeability acceleration 
of deprotonated doxorubicin. The complete loosening of the interfacial area (i.e. the 
completion of gel to ripple phase transition) also matches the temperature at which the 
maximum D/L ratio is reached. Hence, it is hypothesized that, prior to the loosening of 
the highly packed hydrocarbon tail region, the hydrogen-bond network at the interfacial 
region is the rate limiting factor for transmembrane movement of non-ionic molecules 
such as deprotonated doxorubicin. Such drastic changes at the interfacial region, 
however, have little influence on the rate of transmembrane-movement of ionic and 
hydrophilic molecules, as the rate limiting factor lies in  the tight hydrophobic part , which 
remains intact within the 30-36oC  region (i.e. comfort temperature zone).  Still, we 
cannot rule out the possible relation between the potential occurrence of liquid phase at 
Pβ in nanosized vesicles and the increase of permeability of membrane. 
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3.5.2.2. Relation between the potential occurrence of liquidation at ripple phase in 
nanosized vesicle and the permeability change  
 
As discussed above, membrane transition from the solid to liquid phase is usually 
regarded as a two stage process, where the former transition (solid phase to Pβ , marked 
as pretransition temperature, Tp ) results  in the subtle change of the lipid packing and 
the latter transition (Pβ to liquid phase, marked as Tm,) leads to the melting of the lipid.  
However, since the initial discovery of continuous enthalpy reading between two 
transitions (Heimburg. 1998), it has been proposed that both Tm and Tp are related to 
one membrane change (i.e. lipid melting) (Heimburg. 2000). The occurrence and scale 
of cooperative movement, on the other hand, depend on the preparation method of the 
lipid: using DPPC as a membrane component, it has been found that unilamilar vesicles 
with 100nm particle size show a higher cooperativity than its multilamilar  counterpart 
(Heimburg. 2000).  However, it is possible that partially-liquefied membrane during  Pβ is 
unlikely to account for the existence of “comfort temperature zone”: As has been 
reported, the fully-liquefied membrane permit high transmembrane movement of both 
ionic and unionized molecules (Mills and Needham. 2005). Given the low permeability of 
ionic molecules at   the “comfort temperature zone”, it seems unlikely that the property of 
“partially-liquefied” membrane share the same property as its “fully-liquefied” 
counterpart.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
3.5.3. Potential instability of doxorubicin-TSL as a result of ripple phase 
 
Similar to all other thermal sensitive liposomes (Al-Ahmady et al. 2012, Gaber et al. 
1995, Kim et al. 2013, Lindner, et al. 2004, Needham et al. 2000, Tagami et al. 2011), 
doxorubicin-TSLs prepared in this project is the product of two initially separate liposome 
systems:  
 DPPC-based thermal sensitive liposome in which more than 50 mole % 
membrane is composed of DPPC phospholipid. 42oC is the temperature at which 
encapsulated solute is released at the maximum rate. 
 
 PEG.2000-based stealth liposome consisting of 5 mole % of membrane.   
Historically, the selection of DPPC as the main component of thermal sensitive liposome 
is due to the lack of advanced heating method that can avoid irreversible damage to 
normal human tissues brought about by higher temperatures. Since its first application in 
drug delivery systems, DPPC has been adopted as the main component of all thermal 
sensitive liposome formulations (Al-Ahmady et al. 2012, Gaber et al. 1995, Kim et al. 
2013, Lindner, et al. 2004, Needham et al. 2000, Tagami et al. 2011). On the other hand, 
addition of PEGlyated lipid to the membrane is the only method that has been applied to 
prolong the in vivo circulation time of DPPC-based liposome. Till date, whether the 
protective functionality of PEGlyation may be compromised by the usage of DPPC as 
main membrane component is yet unknown.  
 
However, it has been found that the in vivo stability of dox-TSLs is inferior to the 
traditional stealth liposome (PEGlayted liposome with HSPC being its main component): 
using D/L ratio as a parameter, Woo et al demonstrated that dox-TSLs lost 40% of 
encapsulated doxorubicin within 1hr after injection (Woo et al. 2008). On the other hand, 
in the same incubation condition, stealth liposome showed little doxorubicin leakage 
within 1hr after injection (Al-Jamal et al. 2012). As both TSL and stealth liposome have a 
same level of PEG population (~5%), the compromised PEG protection functionality in 
TSL at physiological temperature may result from the selection of DPPC as the main 
component of membrane: The protective functionality of PEGlyation stems from its 
ability to form an additional layer outside of the original membrane, preventing 
undesirable protein adsorption and resultant acceleration of solute leakage (Allen et al. 
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2002). The level of protection PEGlyation offered, on the other hand, relies on the 
density of PEG on the membrane surface. Upon heating, the membrane becomes more 
loosely packed and such transition may dilute the density of PEG on the surface and 
compromise its resultant protection functionality. 
 
In the project, it has been demonstrated that the transition of membrane from the solid to 
ripple phase may significantly alter the resistance of TSL against unprotonated 
doxorubicin and it is likely that such a change is also responsible for the protection 
offered by PEGlyation.  As a result, finding the potential relation between the presence 
of ripple phase and the functionality of PEG layer will become the focus of future work. 
 
 
 
 
3.6. Summary  
The results presented in this chapter demonstrate that the formulation developed can 
encapsulate doxorubicin successfully into thermal sensitive liposomes. The D/L ratio of 
the dox-TSLs prepared in the present study is 2 times higher than most dox-TSLs 
reported in the literature. In order to achieve a high D/L ratio, Incubation temperature 
during vesicle preparation process was found to be critical.  A hypothesis was proposed 
that the ripple phase of DPPC membrane may have contributed to the selective 
permeability increase of unprotonated doxorubicin molecules during incubation process. 
It is also proposed that the functionality of PEG layer on dox-TSLs may be compromised 
at physiological temperature as a result of ripple phase. 
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Chapter 4.  Characterization of dox-TSLs and 
determination of their thermal sensitivity  
 
4.1. Introduction  
 
As described in chapter 3, dox-TSLs were successfully prepared in the current project 
and their D/L ratio was 2 times higher than the D/L ratio of dox-TSLs in the existing 
publications. In addition to D/L ratio, particle size and phase transition temperature of 
liposomes are two properties that usually determined during the development of novel 
thermal sensitive liposomes. This is summarized in table 4.1. Particle size contributes to 
the half-life of vesicles in circulations and 100nm is currently considered as a desirable 
particle size for circulation of thermal sensitive liposome (to be detailed in table 4.2). 
Phase transition temperature (Tm) of liposome membrane is another property that most 
research groups determined during thermal sensitive liposome development. According 
to the current theory, it is believed that thermal sensitive liposomes reach their highest 
permeability to ionic molecules upon heating to the Tm, as a consequence of the 
maximization of solid/liquid interfacial area (Needham et al. 2013). As a result, Tm of 
liposomes needs to be compatible with the external heating source that triggers the 
release of encapsulated material. As mentioned in section 3.5.3, 42 oC is currently the 
desirable Tm of liposome (to be detailed in table 4.2).  In the current studies, both 
properties of dox-TSLs were determined and compared with dox-TSLs in the existing 
publications. It needs to be emphasized in here that, unlike some publications 
(summarized in table 4.1.), zeta potential (i.e. electro potential) of dox-TSLs was not 
measured in the current studies as the stability of DSPE.PEG.2000-based liposome (e.g. 
dox-TSL, etc) rely on the presence of PEG layer rather than electro potential of 
membrane (mentioned in section 3.5.3).   
 
On the other hand, the performance (i.e. thermal sensitivity) of dox-TSLs upon heating is 
the most important properties of dox-TSLs. In the present studies, the thermal sensitivity 
of dox-TSL was determined using two heating method and potential doxorubicin release 
mechanism was also discussed.   
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Table 4.1. Summaries of property determination during novel thermal sensitive liposome 
development in existing publications  
Component of formulation  
 
Selected Publication  
 
Properties determined 
 
 
Phase 
transition 
temperature 
Particle 
size 
Zeta 
potential 
DPPC:MPPC:SPE.PEG.2000 
(85:10:5) 
Anyarambhatla and 
Needham. 1999 
√ √  
DPPC:DSPC:DSPE.PEG.2000 
(80:15:5) 
Hossann et al 2007 √ √ √ 
 
EPC, Chol (7:3) with various 
molar ratio 
of  
poly(EOEOVE)-OD
1
 
 
Kono et al . 2010 √ √  
DPPC/ Brij
®
S20
2
 
Tagami et al. 2011 
 
√ √  
DPPC/DSPC/ DSPE-PEG2000 
(90:10:5)  with various molar of 
Lp-peptide
3
 
 
Al-Ahmady et al 
.2012. 
 
√ √ √ 
1. poly(EOEOVE)-OD represents poly[2-(2-ethoxy)ethoxyethyl vinyl ether (EOEOVE)].  
2. Brij
®
 S20 represents  PEGylated single-chain surfactants attached with C-18 fatty acid chain.  
3. Lp-peptide
 
represents a type of lipid-anchoring temperature-sensitive amphiphilic peptide . The 
amino acid sequence [VSSLESKVSSLESKVSKLESKKSKLESKVSKLESKVSSLESK]- NH2 
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4.2. Selection of characterization method for doxorubicin encapsulate vesicle  
4.2.1. Determination of particle size of liposome  
 
Photon Correlation Spectroscopy (PCS) is based on a dynamic light scattering 
mechanism and the time decay of the near-order of the particles caused by the 
Brownian motion is used to evaluate the size of nanoparticles via the Stokes-Einstein 
relation (Sympa TEC note, available on www.sympatec.com). Brownian motion is 
defined as the random movement of the particles in a fluid that results from the collision 
of surrounding solvent molecules and is usually measured in terms of a diffusion 
coefficient. Light scattered by the particles in the sample produces a speckle pattern due 
to the addition and cancelation of scattered light. The intensity of fluctuation of speckle 
pattern provides information on the diffusion velocity (i.e. Brownian motion) of the 
particles (DSL technical note, available online from http://www.malvern.com).  
 
However, direct application of the frequency spectrum is inadequate to determine the 
diffusion rate of particles due to the decaying of diffusion velocity with time (DLS 
technical note, available at http://www.malvern.com). Through the application of a 
correlator, the correlation function G of the scattered intensity can be constructed based 
on the decay time of the sample (Duffy. 2009). By treating autocorrelation function as a 
single exponential decay, the diffusion velocity of the sample is obtained, from which the 
diffusion coefficient of the particle size can be obtained (Duffy. 2009). 
 
4.2.2. Determination of phase transition temperature of liposome  
 
The total area of the solid-liquid interface reaches its maximum at the phase transition 
temperature. For LTSL, a significant reduction of permeability has been reported when 
the temperature deviates from the phase transition temperature (Mills and Needham. 
2005). Hence, in order to study the maximum permeability of liposomes, it is necessary 
to determine the phase transition temperature of lipid membrane and this can be 
achieved by using differential scanning calorimetry (DSC). DSC is a thermal analytical 
technique that measures the difference of heat flow required to increase the temperature 
of a sample when compared to that of a reference material (Gill et al. 2010). The melting 
of crystalline liposome involves the absorption of energy, which can be determined by 
DSC in the form of heat flow against temperature (Anyarambhatla et al. 1999). 
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4.3. Selection of assay to study thermal sensitivity of doxorubicin-encapsulated 
liposome 
 
Doxorubicin molecules that are encapsulated in the interior of liposomes cannot interact 
with tumour cells until they permeate through the liposome membrane. In the case of 
thermal sensitive liposomes, the extent of doxorubicin release depends on the 
permeability of membrane and its variation with temperature (i.e. thermal sensitivity of 
liposome). This molecule-releasing process is similar to the dissolution process of the 
drug in its conventional formulations that have a visible form (e.g. tablet, granulated 
powder in capsule, etc).   
 
4.3.1. Incompatibility of dissolution test with thermal sensitive liposome   
 
In pharmaceutical industry, dissolution tests are used to measure the rate of mass 
transfer from its physical dosage form to molecular form under a certain temperature and 
solvent composition (Ravindran. 2011). In dissolution study, drug formulation is 
physically separated from the released drug molecules, with the latter being extracted 
from the bulk solution and quantified using appropriate quantification method. The 
selection of equipment to study the dissolution process of conventional drug formulations 
is regulated by the Food and Drug administration (FDA) in US (Dissolution Methods 
Database, available from http://www.fda.gov/). Currently, however, the principle of 
dissolution test is not compatible with thermal sensitive liposome due to the lack of 
appropriate separation material. 
 
As none of the FDA-approved separation method is able to separate free drug 
molecules from nano-sized liposome formulation (e.g. metal basket, glass frit, metal 
disk, etc), dialysis bag (usually made of polymerized cellulose) has been used in the 
literature as a separation method to study the release behaviour of liposome formulation 
(Fugit and Anderson. 2014, Modi and Anderson. 2013): During the assay, liposomes are 
introduced into either side of a dialysis bag. Due to their relatively small size, free drug 
molecules are able to pass through the dialysis bag and then extracted from the 
medium, whereas liposomes remain trapped by the dialysis bag.  In US and Europe, 
dialysis bag has been recommended as a separation tool to study the dissolution 
process of nano-sized formulation by various professional organizations, including the 
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European Federation of Pharmaceutical Scientists and American Association of 
Pharmaceutical Scientists (Burgess et al. 2004).    
 
Theoretically, dialysis bag-based dissolution test should be an ideal assay to study the 
thermal release behaviour of doxorubicin-encapsulated thermal sensitive liposomes. In 
practice, however, the diffusion process of doxorubicin molecules through the current 
generation of dialysis bag has been found to be very slow, making it impossible to 
determine the thermal sensitivity of doxorubicin-encapsulated thermal sensitive 
liposome. Using a dialysis bag with cut-off pore size of 6-8 KDa molecular weight (MW), 
doxorubicin molecules (1.2  g/mL) have been determined to slowly diffuse through 
dialysis bag and the whole diffusion process took 5 hours to complete (Manocha, and 
Margaritis, 2010). On the other hand, thermal sensitive liposomes can release majority 
of the encapsulated doxorubicin within seconds (Needham et al. 2013). Till now, no 
publication has been found in the literature that reports the use of dialysis bag to study 
the release behaviour of thermal sensitive liposome.  
 
Fortunately, in the case of doxorubicin-encapsulated liposome, the self-quenching 
nature of the molecule makes it possible to study the release behaviour of doxorubicin 
without the need to physically separate free molecules from liposome formulation.   
 
 
 
 
 
4.3.2. Selection of self-quenching based doxorubicin quantification method  
 
Doxorubicin possesses a strong self-association tendency that leads to the quenching of 
fluorescent intensity due to the stacking and subsequent shielding of the fluorophore 
(Montero et al. 1993, de Smet et al. 2013). As a result, an obvious reduction of 
fluorescence intensity is expected when the concentration of doxorubicin in solution 
exceeds 50 μm (Kitaeva et al. 2004).  After being  encapsulated,  the internal 
concentration of doxorubicin is expected to be much higher than 50 μM and is likely to 
reach 30 mM, if a 10% encapsulation efficiency (initial doxorubicin to lipid ratio is set at 
3:1) has been achieved (Li et al. 1998).  Upon the release of encapsulated doxorubicin, 
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an enhancement of fluorescence intensity would occur if the eventual concentration of 
doxorubicin is set below 50 μM. Hence, the fluorescence intensity difference prior to and 
after doxorubicin release can be used to calculate the amount of encapsulated 
doxorubicin without the need to physically separate free molecules from its liposome 
formulation. This can be simply expressed as:  
𝐹𝐼 − 𝐹0                                                                     <1>    
 
where F0 is the amount of encapsulated material detected prior to heating, and FI is the 
amount of encapsulated material detected after heating. 
 
Since the invention of doxorubicin-encapsulated thermal sensitive liposome (Gaber et al. 
1995), self-quenching based quantification method has become a predominant method 
to study the release behavior of doxorubicin-encapsulated thermal sensitive liposome, 
as summarized in Table 4.2. Due to its ease of use and wide application, fluorescent-
based method was selected as the basic principle to determine the release behavior of 
thermal sensitive liposome in the current study. Unlike the method adopted in most 
publications, however, it was the amount, rather than percentage release of doxorubicin 
that was used as the parameter to compare the thermal sensitivity of different liposome 
formulations, which will be described in detail in the next section.  
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Table 4.2. Summary of prior studies where the thermal sensitivity of doxorubicin-
encapsulated thermal sensitive liposomes was determine based on the self-quenching 
nature of doxorubicin   
Group (Country) 
Notable publication 
by group 
Parameters used to 
determine thermal sensitivity 
of liposome at 42 
o
C  
Needham (U.S) 
Needham et al, 2005 
 
% release of encapsulated 
doxorubicin   
Needham et al. 2000 
 
Needham et al . 2013 
 
Lindner  
(Germany) 
 
Li et al . 2013 
 
`Hossanet al. 2010. 
 
 
Kono (Japan) 
 
 
Kono et al . 2010 
Tagami (Japan) 
 
 
Tagami et al. 2011 
 
 
Kostarelos (UK) 
 
 
AL-AHMADY et al 
.2012. 
 
 
Banno (Canada ) 
 
Banno et al . 2010 
Amount of doxorubicin 
released per lipid (W/W) 
Chiu (Germany) 
 
 
Chiu et al. 2005 
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4.3.3. Selection of parameter to determine the thermal sensitivity of doxorubicin-
encapsulated liposome 
 
In majority of publications (except 2 publications, detailed in Table 4.2), the relative 
thermal sensitivity and stability of thermal sensitive liposome formulations have been 
determined using equation 2:  
 
% release =
𝐹𝐼−𝐹0
𝐹𝑓𝑢𝑙𝑙−𝐹0
× 100%                                                 <2> 
 
where F0 is the amount of encapsulated material detected prior to heating, FI is the 
amount of encapsulated material detected after heating, Ffull  is the total amount of 
doxorubicin detected after complete release of doxorubicin using 1 v/v % Triton X-100. 
 
The % release of encapsulated doxorubicin molecules after pre-determined heating 
process was compared among formulations. A higher % release was considered as an 
indication of higher thermal sensitivity of liposome membrane. Groups worldwide that 
have used the percentage release to measure the thermal sensitivity and stability of 
doxorubicin-encapsulated thermal sensitive liposomes have also been included in Table 
4.2.  However, as a drug that is able to crystalize at low concentration threshold (i.e. 34 
μM), the thermal sensitivity of liposomes cannot be accurately quantified through the % 
release of encapsulated doxorubicin, despite the popularity of this method. 
 
Based on Fick’s law, Lodish et al derived an expression for biological application that 
relates the permeability of biological membrane with the movement of molecules across 
a unit area and time (i.e. flux) (Lodish et al. 2000):  
 
𝐹𝑙𝑢𝑥 =  −𝑃 𝐶                                                                   <3> 
where P stands for the permeability of biological membrane, and C represents the 
concentration gradient of target molecules across the membrane.  
 
According to the equation, if the permeability of membrane remains constant, the flux of 
solute will also remain constant as long as the concentration gradient of solute does not 
change. In the case of doxorubicin-encapsulated liposome prepared by the pH-gradient 
method, crystalized doxorubicin is the major physical form of encapsulated doxorubicin 
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due to their high concentration (>150 mM internal doxorubicin concentration).  As 
crystalized doxorubicin (Doxcrys) and free doxorubicin molecules (Doxfree) can rapidly 
transform into  one another (Li et al. 1998), a reduction in Doxfree during doxorubicin 
release process will result in an increase in Doxcrys, assuming liposome membrane is 
impermeable to Doxcrys.  This makes the concentration of Doxfree (Cdox) constant as long 
as Doxcrys exists (behaving as a supersaturated solution). Consequently, the amount of 
doxorubicin molecules that permeate through the liposome membrane in a given time 
frame will also remain constant irrespective of the doxorubicin/lipid ratio (D/L ratio, W/W) 
and provide a clearer picture of the thermal sensitivity of liposome, when compared with 
% release. This is clearly demonstrated in the paper published by Johnston’s group 
(Johnston et al. 2008), where doxorubicin was encapsulated in liposomes composed of 
distearoylphosphatidylcholine (DSPC) and cholesterol. Using 2mM ammonium chloride 
as incubation medium, % release of doxorubicin-encapsulated LUVs at three D/L levels 
(0.39, 0.1 and 0.047 W/W) was used as an indicator of formulation stability and it was 
concluded that higher D/L ratio was associated with better overall stability, as 
demonstrated in Figure 4.1.A.  However, when comparing the value of fluxdox for the 
three formulations, different conclusions could be made. Shown in Figure 4.1.B is the 
fluxdox (mg) vs. time based on the same data obtained by Johnston et al., and it 
demonstrates that more doxorubicin is released from high D/L ratio formulations. In 
addition, formulations with a low and medium D/L ratio have a similar outward 
doxorubicin flux and hence membrane permeability, which is consistent with the 
supersaturated condition of encapsulated doxorubicin solution.  Abnormal morphology of 
doxorubicin crystal was found to occur at higher D/L ratio which may be responsible for 
increased membrane permeability (Johnston et al. 2008).  
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Figure 4.1. Influence of D/L ratio on stability of liposomal doxorubicin using % release (A) 
or amount of released doxorubicin/lipid (w/w) (B). Both graphs were reconstructed using 
the data reported by Johnston et al (Johnston et al. 2008).  
  
 
In summary, the amount of doxorubicin released from liposome (mg of doxorubicin/lipid 
w/w) will be used in the present project to determine the thermal sensitivity of liposome 
upon heating.  
 
   
4.3.4. Selection of heating method to determine the release behavior  
 
To mimic the preferred vesicle delivery strategy (intravascular release, detailed in 
section 2.3.1.2), an ideal heating method to determine the response of thermal sensitive 
liposome is to directly immerse liposomes in buffer solution that is at a uniform 
hyperthermia temperature, in conjunction with real time-monitoring of fluorescent 
changes of buffer solution.  However, a fluorescent detection system that is able to 
simultaneously detect fluorescent signal of incubated solution upon introduction of 
another substance without affecting its temperature is not readily available in the 
Department. Therefore, the thermal sensitivity of liposome solution was determined 
using two separate heating methods:  progressive heating and direct heating.  
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4.3.4.1. Progressive heating method 
 
In this assay, Liposomes-containing vial was immersed in a temperature-equilibrated 
water bath. Change of fluorescent signal was then used to determine the amount of 
doxorubicin release at a fixed time point during heating. In this heating assay, thermal 
sensitivity of liposomes during the heating process (heated from room temperature to 42 
oC) was measured.  
 
4.3.4.2. Direct heating method 
 
In this heating assay, a small volume of liposome solution (20µl) was directly injected 
into a relatively large volume of buffer solution (1.5 ml) that had been temperature-
equilibrated for 15 min. After a short period of time (10 seconds), the whole buffer 
system was then quickly transferred to an ice bath and its fluorescent reading was 
recorded. Compared with the progressive heating method, direct heating provides 
clinically relevant data as it mimics the intravascular release strategy that is used to 
thermally trigger the release of thermal sensitive liposome in clinical trials. In addition, 
temperatures above the phase transition temperature of liposome membrane were used 
as incubation temperature during direct heating. This would make the performance of 
liposome more clinically accessible not only to HIFU that is able to accurately heat tissue 
at a well-controlled temperature range, but also RFA , a heating method that has a wider 
temperature distribution when used as an external heating source (detailed in section 
1.4).  
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4.4. Analytical process of doxorubicin-TSL  
This section describes in detail the analytical process for the properties and performance 
of liposomal doxorubicin. 
 
4.4.1. Determination of particle size of liposome  
 
Liposome solution (20 µl) was diluted in buffer solution (1 ml, HEPES buffer) and  put in 
a BrandTech® disposable UV Cuvette. Cuvette was then placed in a sample cell of PCS 
(Zetasizer Nano S, Malvern ).  Refractive index was set at default liposome solution and 
incubation temperature was set at 25 oC. Detection angle was set at 173 o. Z-average 
size (hydrodynamic diameter, nm) and pDI (polydispersity index ) are the two 
parameters used in this project to describe the particle size of liposomes. The data was 
calculated automatically, according to the intensity distribution of measured solution.  
 
4.4.2. Determination of phase transition temperature of TSL membrane 
 
Stock lipid chloroform solutions, with a total of 10 mg lipid were mixed in round-button 
flask and solvent was then removed using a rotary evaporator to form a dried thin layer. 
Dried layer was then scratched from the flask (around 1.5 mg) and was added into 
aluminium pan made for DSC measurement. 100 wt % (~1.5 ml) of deionized water was 
added into the dried lipid and pan was clip-sealed.  The sample-containing pan was then 
introduced into the sample cell of differential scanning calorimeters (Dsc q 2000, TA 
instrument). Empty sample aluminium pan was used as reference sample. The mixture 
was allowed to hydrate at 60 oC for 1 hour. Sample was then cooled to 30 oC and its 
heat flow was measured at a heating rate of 1oC/minute from 30 oC to 60 oC.   
 
4.4.3. Determination of release behaviour of doxorubicin-TSL 
4.4.3.1. Progressive heating assay 
 
Liposome solution (100 µl) was diluted in buffer solution (5 ml, HEPES buffer) and each 
1 ml sample was placed separately in a small glass vial.  Liposome containing vial was 
then immersed in a temperature-equilibrated water bath. The vial was taken out from the 
water bath at pre-determined time points and then quickly transferred into an ice bath to 
arrest release. All samples were then allowed to equilibrate with room temperature 
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(~25oC) prior to measurement of fluorescence intensities (480 nm excitation and 555 nm 
emission) using a fluorometer (LS-55 spectrometer, Perkin Elmer).  The amount of 
doxorubicin released was determined using equation 1. The total amount of 
encapsulated doxorubicin was obtained through the addition of 1 v/v % Triton X100 
using equation 1. 
 
4.4.3.2. Direct heating assay 
 
1.5 ml of HEPES buffer was placed in a 15ml plastic centrifuge tube and immersed in a 
water bath that was already equilibrated at a desired temperature.  Buffer was then 
heated for 15 min before 20 µl of liposome solution was added into the buffer solution. 
Mixture was heated for 10 seconds and was quickly transferred into a glass vial 
stationed in an ice bath to stop heating.  The percentage doxorubicin release was 
calculated based on the fluorescence intensity of the sample after heating to that treated 
with 1 v/v % Triton X100. 
 
 
4.5 Results and discussion  
4.5.1 Characterization of dox-TSL and dox-LTSL 
 
The D/L ratio, particle size of dox-TSLs as well as the phase transition temperature of 
TSL membrane were determined and relevant results are summarized in Table 4.3. The 
properties of dox-TSLs prepared by other groups are also included in Table 4.3 for 
comparison. Compared with TSLs prepared by other groups, it is clearly demonstrated 
that an optimized incubation process (36 oC for 1 hour) significantly increased the 
amount of doxorubicin encapsulated in the TSL vesicles, increasing the D/L ratio of dox-
TSLs from normally reported 0.05 to 0.123 (doxorubicin/ lipid w/w). On the other hand, 
the achieved D/L ratio enhancement seems to have little effect on the hydrodynamic 
diameter of dox-TSLs in comparison with dox-TSLs with lower D/L ratio. The validity of 
liposome destruction method (adding 1% V/V triton into the solution) was determined by 
changes in dox-TSLs size prior to and after the addition of triton. Prior to the addition of 
triton, hydrodynamic diameter of dox-TSLs was 110 nm. After the addition of triton, the 
particle size of the same dox-TSLs solution dramatically reduced to 10.3 nm. This 
indicates that dox-TSLs were destroyed and formed into micelles upon the addition of 
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triton, releasing encapsulated doxorubicin.  The total release of encapsulated 
doxorubicin was also visually noticeable through colour changes of the liposome 
solution, as demonstrated in Figure 4.2. 
 
 
 
 
 
Figure 4.2. Physical appearance of intact dox-TSLs (A), dox-TSLs after the addition of 
triton X-100 (B) and dox-TSLs after 2 minutes of progressive heating assay. Intact dox-TSL 
have unique pink colour. dox-TSLs solution that was either lysed or heated has an orange 
colour that resembles pure doxorubicin solution.  
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Table 4.3. Characterization of liposomal doxorubicin prepared in the present study and 
comparison with publications in the literature.   
 
Composition 
 
Dox/lipid  
ratio 
(W/W) 
Particle size 
Tm 
$
(
o
C) Reference hydrodynamic 
diameter (nm) 
 
Polydispersity 
index 
 
DPPC:DSPE.PEG.2000 
(96:4) 
 
0.123 
±0.034* 
 
 
110 ±1.002*  
 
 
0.18 ± 
0.005* 
 
  42.179 
± 0.0012^   
 
Present 
study 
 
DPPC:DSPE.PEG.2000 
(100:4) 
0.05 N/A N/A 
 
Banno et 
al. 2010 
 
DPPC:DSPE.PEG.2000 
(95:5) 
0.05 N/A N/A 
 
Chiu et al. 
2005 
 
DPPC:DSPE.PEG.2000 
(96:4) 
N/A N/A 41.7 
 
Needham 
et al. 
2013 
 
DPPC: MSPC: DSPE-
PEG2000 
(86:10:4) 
0.139 
±0.032 
 
110±1.185 
 
0.22±0.015 
 
 
N/A 
 
Present 
study 
 
DPPC: MSPC: DSPE-
PEG2000 
(90:10: 4) 
0.05 N/A  N/A 
 
Banno et 
al. 2010 
 
DPPC: MSPC: DSPE-
PEG2000 
(86:10:4) 
 
0.05 
 
101.5 ± 0.9 
 
0.06 ± 0.01 
41.5 
 
Al-Jamal 
et al. 
2012 
 
The results are expressed as mean ± standard deviation.  * Measurement was don done with n=3. 
^ Measurement was don done with n=2. 
$ 
Tm stands for phase transition temperature of liposome 
membrane,  
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The phase transition temperature (Tm) of TSL membrane was determined to be 42.1799 
oC.  The Tm of pure DPPC membrane was also determined to be 42.2226 
oC and the 
addition of 5% of DSPE.PEG2000 lipid had little effect on the overall Tm of lipid 
membrane. Detailed DSC graphs of TSL and DPPC membrane are given in Appendix 
VII and VIII, respectively.   
 
Dox-LTSLs prepared in the current study had similar characteristic to their dox-TSL 
counterpart and the relevant data are also presented in Table 4.3. Due to time 
constraint, however, phase transition temperature of LTSL membrane was not 
determined.  
 
4.5.2. The determination of dox-TSL release behaviour 
4.5.2.1. Release behavior of dox-TSL and dox-LTSL using progressive heating method 
 
Whether the TSL vesicles developed in this project are good doxorubicin carriers or not 
depends on their ability to rapidly release the encapsulated doxorubicin upon heating. It 
needs to be emphasized here that as a result of their ultrafast release rate (within 
seconds, to be illustrated in section 4.5.2.5), the thermal sensitivity of TSLs and LTSLs is 
not expected to be compared with that obtained by directly immersing liposome solution 
into temperature-equilibrated buffer solutions. Rather, the doxorubicin release behavior 
of liposomes during progressive heating  provided an opportunity to compare the relative 
performance of TSLs and LTSLs as a result of the slow heating process. The release 
behaviors of both formulations in progressive heating were determined and are 
presented in Figure 4.3.   
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Figure 4.3. Amount of doxorubicin released per lipid (w/w) from dox-TSL (n=3) and dox-
LTSL (n=5) at 42°C using progressive heating method. Standard deviation was too small to 
be shown on the graph.  
 
 
Unexpectedly, dox-TSLs prepared in this project was able to release majority of the 
encapsulated doxorubicin during 2.5 minutes heating at a rate that was faster than their 
LTSL counterpart:  After 1.5 minutes of heating, TSLs were able to release 0.1 mg of 
doxorubicin per mg of lipid, while LTSLs only released around half that amount of 
doxorubicin (0.056 mg of doxorubicin per mg of lipid).  After 2 minutes of heating, around 
88 % of encapsulated doxorubicin was released from TSLs as was evident from the 
color changes of the solution (Figure 4.2). Based on the obtained results, it seems that 
the addition of 10% of lysolipid (MPSC) stabilized the liposome membrane upon heating 
and slowed the release of encapsulated doxorubicin. While unexpected, it was not the 
first time that lysolipid-free thermal sensitive liposome was reported to have higher 
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thermal sensitivity than its LTSL counterpart. This is further discussed in the next 
section. 
 
4.5.2.2. Reported superior thermal sensitivity of TSL in comparison with LTSL 
 
A selection of existing publications that reported the superior thermal sensitivity of lyso-
lipid free thermal sensitive liposome in comparison with LTSL have been summarized 
and listed in Table 4.4. Using a simple HEPES buffer as incubation medium, Dox-TSLs 
prepared by Chiu et al released 6 µg of doxorubicin/ mg of lipid after 30 minutes 
incubation at physiological temperature (i.e. 37 oC), whereas Dox-LTSLs released less 
than 2.5 µg of doxorubicin/ mg of lipid under the same incubation condition (Chiu et al. 
2005 ). Similarly, using fetal calf serum as incubation medium,  dox-TSLs prepared by Li 
et al were able to release 0.104 mg of doxourubicin/ mg of lipid after 5 min heating at 41 
oC, while Dox-LTSLs were only able to release 6.5 µg of doxorubicin/ mg of lipid (Li et al. 
2013). Cisplatin molecules, another chemotherapy agent, were also found to be able to 
permeate through TSL membrane three times faster in comparison with LTSL when 
heated at 37 oC (Woo et al. 2008). Hence, according to the data presented in Table 4.4, 
TSLs appear to have higher thermal sensitivity within the temperature range of 37 to 42 
oC. This conclusion is consistent with the results obtained in the progressive heating 
method (i.e. heating the glass vial that contains liposome to 42 oC using water bath). As 
doxorubicin and MSPC can incorporate into the DPPC-based membrane, it is possible 
that MSPC acts to “protect” the membrane from doxorubicin incorporation, which would 
otherwise compromise the thermal response of liposome. This will be discussed in 
section 4.5.2.4. 
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Table.4.4 summary of prior studies that demonstrate lysolipid-free thermal sensitive 
liposome having faster release rate  than LTSL at various temperature points 
Group 
Membrane 
composition/  
Encapsulated 
material 
Temperature 
and 
incubation 
time 
Incubation 
media 
Amount of 
TSL mg/ml  
Amount of 
LTSL 
Li et al.2013 
Doxorubicin 
 
37 (60 min) 
 
50 % fetal 
calf serum 
0.04 0.03 
41 (5 min) 
 
99 % fetal 
calf serum 
0.104 0.065 
Chiu et al. 
2005 
37 (30 min) 
 
HEPES 
buffer 
0.006 0.0025 
 
 
Woo et 
al.2008 
 
Cisplatin 
 
37 (30 min) 
 
 
HEPES 
buffer 
 
0.00375 
 
 
0.00125 
 
Hossann et 
al. 2010 
Carboxy-
fluorescent 
42 (5 min) 
 
 
 
5% glucose/ 
fetal calf 
serum (FCS) 
1:1 (vol/vol) 
0.054 0.045 
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4.5.2.3. Existing reports on interaction of doxorubicin and lysolipid with DPPC membrane 
 
Apart from its ability to interact with DNA, being able to disrupt membrane of target cell is 
another vital cytotoxic mechanism of doxorubicin. This has been determined both in 
artificial liposome system as well as in pathological tumor cell models. In 1989, Dupou-
Cezanne et al carried out a study to determine whether doxorubicin molecules would 
interact with liposome composed of egg phosphatidylcholine (egg PC) and cholesterol 
(Dupou-Cezanne, et al. 1989). By measuring energy transfer of paired fluorescent 
probes, doxorubicin was found to penetrate the lipid bilayer with its 
dihydroanthraquinone group being inserted into the hydrocarbon part of liposome. Later 
in 1992, Awasthi et al measured the partition of radio-labeled doxorubicin molecules in 
lipid membrane and cytosol part of fibroblast cells (Awasthi et al. 1992). The ratio of 
membrane/cytosolic concentration was above 30 and such parameter correlated well 
with cell’s susceptibility to doxorubicin (Awasthi et al. 1992).  In the theoretical field, 
pioneering simulation work was performed by Yacoub et al to study the potential 
interaction site of DPPC membrane with doxorubicin molecules (Yacoub et al. 2011): 
Using molecular dynamic simulations, changes in DPPC membrane structure were 
studied in the presence of doxorubicin molecules at 50 oC. Unlike its egg PC 
counterpart, DPPC molecules also interact with the polar site of doxorubicin (e.g. 
hydroxyl, ketone, etc) through electrostatic force, as illustrated in Figure 4.4. 
Consequently, DPPC-doxorubicin interactions reduce the area occupied by each 
phospholipid molecule from 63 Å to 57 Å.  
 
On the other hand, as a phospholipid analogue, lysolipid was expected to incorporate 
into the DPPC-based membrane in a similar way to its phospholipid counterpart (Mills 
and Needham. 2005). While lacking experimental work, coarse-grained molecular 
dynamic simulation has been carried out to study the structural change of DPPC bilayer 
upon the addition of MPPC (16-carbon lysolipid) (Winter and Schatz. 2010). 
Interestingly, similar to the effect of doxorubicin, the incorporation of 10 mol % of MPPC 
also reduced the area per phospholipid molecule from 65 Å to 60 Å (Winter and Schatz. 
2010). Considering the similar effect of doxorubicin and lysolipid on DPPC membrane, 
why insertions of doxorubicin increase the thermal sensitivity of DPPC membrane?  
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Figure 4.4.  Potential interaction of doxorubicin and lysolipid (MSPC) with DPPC lipid. 
Dihydroanthraquinone group of doxorubicin was found to interact with hydrophobic tail of 
egg PC (Dupou-Cezanne, et al. 1989). Simulation studies showed that the polar group of 
doxorubicin could interact with hydrophilic part of DPPC membrane (Yacoub et al. 2011). 
Lysolpid interacts with DPPC lipid as its two-fatty acid chain counterpart (Winter and 
Schatz. 2010).  
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4.5.2.4. Potential mechanism behind the superior thermal sensitivity of dox-TSL  
 
In the presence of lysolipid-free liposome analogues (e.g. red blood cell), lysolipids tend 
to leave their originally-incorporated DPPC membrane and migrate to lysolipid-free 
membrane. This membrane-membrane movement of lysolipid was first reported by 
Sandstrom et al and was defined as desorption tendency of lysolipid (Sandstrom et al. 
2005): After incubating LTSLs (donor membrane of lysolipid) for 1 hour in a liposome-
containing medium, where  the liposome was composed of egg PC (acceptor membrane 
of lysolipid), LTSLs lost 50% of their originally incorporated lysolipids. On the other hand, 
LTSLs suffered little lysolipid reduction after 1 hour-incubation in a simple buffer solution 
(donor membrane of lysolipid was absent) (Sandstrom et al. 2005). Later on, the 
physiological impact of lysolipid desorption on dox-LTSLs stability was studied by Bann 
et al (Banno et al. 2010):  Using blood as incubation medium (with red blood cell as 
acceptor membrane), it was found that more than 50% of the encapsulated doxorubicin 
was lost after 5 minutes incubation at 25 oC, which was accompanied by 50% reduction 
of membrane-incorporated lysolipids. On the other hand, LTSLs incubated in serum (in 
the absence of red blood cell) lost less than 5% of encapsulated doxorubicin. What can 
be learned from these two papers is that, the presence of acceptor membrane (e.g. egg 
PC liposome, red blood cell, etc) creates a lysolipid concentration gradient that enables 
the membrane-membrane migration of lysolipids (from donor membrane to acceptor 
membrane). In addition, desorption of lysolipids creates vacancies in donor membrane, 
resulting in leakage of encapsulated material. Without an acceptor membrane (as in the 
case of simple buffer solution), there would be no concentration gradient of lysolipid, 
hence no migration of lysolipids.   
 
As described in section 4.5.2.3, doxorubicin molecules have the ability to incorporate 
into DPPC-membrane (Doxmem). Unlike their membrane-bound lysolipid counterpart, as 
long as the concentration of Doxmem is higher than either side of the membrane, Doxmem 
can leave their originally incorporated membrane and enter the bulk solution. In other 
words, desorption movement of Doxmem does not require the presence of an acceptor 
membrane. Similar to the desorption movement of membrane-bound lysolipids, 
desorption of Doxmem may also create vacancies in donor membrane, resulting in 
leakage of encapsulated agent.  
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As lysolipid and doxorubicin incorporate into membrane in a similar fashion, the pre-
existence of membrane-bound lysolipids may reduce the amount of doxorubicin that can 
be incorporated into the membrane (both molecules compete for the same incorporation 
site). Therefore, it is reasonable to suggest that dox-LTSLs have less membrane-bound 
doxorubicin molecules when compared with their dox-TSLs counterpart. During 
progressive heating, the thermal release behavior of dox-TSLs and dox-LTSLs were 
determined in simple buffer condition (i.e. no acceptor membrane was present). Hence, 
membrane-bound lysolipids of dox-LTSLs have no desorption tendency and effect on 
the release behavior of encapsulated doxorubicin. On the other hand, both dox-TSLs 
and dox-LTSLs have membrane-bound doxorubicin molecules that are able to desorb 
from their originally-incorporated membrane during the heating process. As a result of 
their higher concentration of Doxmem, dox-TSLs might create more vacancies after 
desorption of Doxmem, thereby increasing their apparent thermal sensitivity in comparison 
with their dox-LTSLs counterpart, which has less Doxmem. This proposed theory is 
demonstrated in Figure 4.5 
 
 
Figure 4.5. Proposed theory that explains why thermal sensitivity of dox-TSLs is higher 
than that of dox-LTSLs. Only doxorubicin molecules are incorporated in the membrane of 
TSLs (Doxmem). During heating, desorption of Doxmem from the membrane leaves vacancies 
that may accelerate the release of doxorubicin upon heating. In the case of dox-LTSLs, 
existence of lysolipids reduce the amount of Doxmem in comparison with dox-TSLs and this 
reduces the thermal sensitivity of dox-LTSL upon heating. 
heating 
heating 
LTSL 
TSL 
86 
 
4.5.2.5. Percentage release of doxorubicin by direct heating method  
 
While the results obtained by progressive heating method provide a relative thermal 
responsive behaviour of dox-TSLs and dox-LTSL when heated from 25 oC to 42 oC, it 
does not represent the actual release behaviour of dox-TSLs upon heating under in vivo 
conditions.  In order to observe the thermal sensitivity of dox-TSLs in a more clinically 
relevant environment, the percentage release of doxorubicin from dox-TSLs and dox-
LTSLs at 45 and 48 oC was obtained using direct heating assay and the results are 
illustrated in Figure 4.6 
 
 
Figure 4.6. Percentage released of encapsulated doxorubicin from dox-TSLs and dox-
LTSLs using direct heating assay (n=3). A small volume of liposome solution (20 µl) was 
directly introduced into a larger volume of buffer (1.5 ml) that was temperature equilibrated 
at desired temperatures in the hyperthermia range.  
 
It should be noted that, during direct heating assay, only % release of encapsulated 
doxorubicin was determined, while the amount of released doxorubicin per lipid was not 
measured.  This was due to the lack of lipid quantification method during direct heating. 
Hence, Figure 4.6 does not provide information regarding the relative thermal sensitivity 
between dox-TSLs and dox-LTSLs. On the other hand, the results clearly demonstrate 
the fast release behaviour of both formulations in an in vivo -mimicking environment: 
Both dox-TSLs and dox-LTSLs released around 80% of the encapsulated doxorubicin 
within 10 seconds after liposome solution was added into buffer solution that was 
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maintained at 45 oC. At 48 oC, the % of doxorubicin released from dox-TSL reduced to 
67%, whereas dox-LTSLs were still able to release 80% of encapsulated doxorubicin. 
Descpite of the 10% reduction of released doxorubicin from dox-TSLs at 48 oC, these 
results demonstrate the ability of dox-TSLs to release considerable amount of 
doxorubicin  after a short period of direct heating at temperature above Tm of liposome 
membrane (i.e. ~42 oC). This finding does not support the current theory that explains 
the thermal sensitivity of TSL, which states that thermal sensitivity of liposome at a fixed 
temperature is directly proportional to the area of the solid/lipid interface of the 
membrane (Mills and Needham. 2005). 
 
4.5.2.6. Current theory that explains thermal sensitivity of liposome and a potential new 
explanation  
 
In their pioneering paper (Mills and Needham. 2005), Mills and Needham determined 
that the permeability of dox-LTSLs to encapsulated doxorubicin increased dramatically 
from 5 x 10-12 to 2.5 x 10-11 moles/s when incubation temperature was increased from 37 
oC to 42 oC (Mills and Needham. 2005).  Further increasing the temperature beyond Tm 
significantly reduced the permeability of dox-LTSLs to encapsulated doxorubicin, 
dropping almost to zero at 43 oC (Mills and Needham. 2005). Hence, it was proposed 
that the maximization of solid/liquid interface in the liposome membrane was responsible 
for the maximization of membrane permeability at Tm. In addition, any deviation of 
temperature from Tm would result in a reduction of membrane permeability as a result of 
reduction of solid/liquid interface area. Under the possible influence of this hypothesis,  
subsequent studies that involved the development of thermal sensitive liposome rarely 
determined the release behavior of liposome at temperatures beyond Tm of the 
membrane.    
 
More recently however, various groups have discovered that the ability of LTSLs and 
lysolipid-free thermal sensitive liposomes to rapidly release encapsulated material was 
not compromised at temperature that exceeded Tm of the liposome membrane. A list of 
existing publications that reported uncompromised release rate of thermal sensitive 
liposome above Tm is summarized in Table 4.5. Therefore, according to data presented 
in Figure 4.6 and information summarized in Table 4.5, it is possible that parameters 
other than the area of solid/liquid interface is responsible for the permeability 
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enhancement of liposome membrane, a parameter which is not significantly altered by 
temperatures above Tm. The area occupied by a single lipid (i.e. area/lipid) is one of the 
potential parameters: Using the small angle neutron and x-ray scattering technique, the 
area/lipid of pure DPPC membrane was found to change little  within the temperature 
range of 50 oC to 60 oC (Kučerka et al. 2011), whereas a dramatic enhancement of 
area/lipid was discovered near Tm of membrane (Kučerka et al. 2011). This finding was 
also theoretically determined by Winter and Schatz using a coarse-grain boundary 
simulation (Winter and Schatz. 2010). As measurements using direct heating  was only 
made at two temperature points (i.e. 45 oC and 48 oC), a direct correlation between any 
changes of area/lipid and thermal sensitivity of dox-TSLs cannot be made. In the future, 
the release behaviour of dox-TSL within the temperature range of 45 oC to 50 oC can be 
studied in detail, in order to find the parameters that are responsible for the rapid release 
behaviour of thermal sensitive liposome.  
 
Table 4.5. List of existing publications that reported thermal sensitivity of liposome being 
uncompromised at temperatures above Tm of membrane.  
Membrane 
Component  
(mole percentage) 
Encapsulated 
material 
Temperature 
range at which 
thermal 
sensitivity of 
liposome 
remained   
maximum (
o
C) 
Phase 
transition 
temperature 
of membrane 
(
o
C) 
Reference 
 
DPPC:HSPC:MSPC:DSPE-
PEG2000  (73.6:18.4:4:4) 
Calcein 
 
40-43 
 
N/A 
 
Chen et al. 
2014 
 
DPPC: DSPC:DSPE-
PEG2000 ( 80:15:5) 
Doxorubicin 
 
40-45 
 
N/A 
Li et al. 
2013 
DPPC:MSPC:DSPE-
PEG2000 (86:10:4) 
Doxorubicin 
 
40-45 
 
N/A 
Li et al. 
2013 
DPPC : DPPG (70:30) Mitomycin C 
 
42-45 
 
N/A 
Hosokawa. 
2003 
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 4.6. Conclusion  
The results presented in this chapter demonstrate two other properties of liposomes that 
usually measured during thermal sensitive liposome development. The particle size of 
phase transition temperature of dox-TSL prepared in the present study is similar to the 
result reported in the existing publications. Using a progressive heating method, it has 
been found that dox-TSLs prepared in the present study have higher thermal sensitivity 
than their dox-LTSLs counterpart. This is consistent with various existing publications. 
Using a direct heating method, it has been determined that both dox-TSLs and dox-
LTSLs are able to rapidly release encapsulated doxorubicin at a heating temperature 
that exceeds the Tm of lipid membrane. This finding supports the recent findings that Tm 
is not the only temperature point at which membrane permeability is at its highest.  
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5. Development of tissue plasminogen 
activator-encapsulated TSL for thrombolysis 
 
5.1. Introduction 
 
The aim of the second part of this project is to design tPA-encapsulated thermal 
sensitive liposomes (i.e. tPA-TSL) that are able to encapsulate tPA molecules in the 
interior of vesicles and to release the encapsulated tPA upon heating. It is also 
necessary to have an appropriate amount of tPA exposed on the surface of the 
liposomes for blood clot targeting. Work carried out in this PhD project constitutes a 
feasibility study of a potentially novel thrombolysis therapy, in which hyperthermia will be 
introduced at pathological blood clot site, activating the release of encapsulated tPA 
from tPA-TSL.  
 
As a well-studied tPA-liposome complex, tPA-ELIP has been found to offer effective tPA-
fibrinogen interaction (Smith et al. 2010). Hence, even without the application of 
ultrasound, tPA-ELIPs may still lysis haemostatic blood clots without severely 
compromising the efficiency of tPA so that the side effect of tPA is not adequately 
controlled. In comparison, encapsulating a large quantity of tPA into the interior of the 
liposome prohibits the availability of the majority of tPA prior to the introduction of 
hyperthermia which is aimed at the targeted clot only. Hence, even if undesirable binding 
with haemostatic blood clots may still occur, this would be significantly limited since the 
encapsulated tPA will not be available until its release is activated by localized 
hyperthermia.  
 
On the other hand, unlike tPA-Ns which are designed to be shear sensitive and  require 
a high shear stress (usually experienced in a narrowed vessel) to trigger the release of 
tPA (Korin et al. 2012), tPA-TSLs release the encapsulated tPA upon temperature rise 
and are expected to be insensitive to the morphology of the blood clot they adhere to.  
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5.2. Development of TSL for thrombolytic agents  
 
This section describes the rationale behind the selection of a pilot thrombolytic agent 
prior to the utilization of tPA and preparation method of vesicles. Methods to quantify the 
thrombolytic agent and thermal sensitivity of thrombolytic agent-encapsulated TSL will 
also be described in detail.   
 
5.2.1. Selection of streptokinase as a pilot  thrombolytic agent  
 
Although the development of a tPA encapsulated TSL system was the main goal of the 
second part of the project, as a result of its high cost, tPA  was not initially used to 
determine the proof of concept of thrombolytic agent-encapsulated TSL. Instead, a much 
cheaper thrombolytic agent (i.e. streptokinase) was selected to determine the feasibility 
of the concept, as well as the related preparation and quantification methods.  
 
Streptokinase (SK) is a bacteria-produced blood clot reducing enzyme that is able to 
directly convert plasminogen to plasmin without the presence of fibrin network (Crabbe 
et al. 1990).  Despite of its potent thrombolytic effect, the clinical application of SK has 
been seriously limited owing to its non-specificity to fibrin-bound plasminogen, which 
results in systematic conversion of circulating plasminogen to plasmin and increased risk 
of internal bleeding (Holt et al. 2012). Furthermore, the bacteria nature of SK has been 
reported to be responsible for the activation of immune response in some patients. This 
not only diminishes the efficiency of SK after initial injection, but also causes 
hypotension (Gemmill et al. 1993).  It has been recently found, however, by deleting 59 
NH2-terminal residues, the resultant SK molecules, i.e., rSKΔ59, is able to selectively 
convert fibrin-bound plasminogen as the ability to activate plaminogen in the absence of 
fibrin is removed (Sazonova et al. 2004, Reed et al. 1999).  In addition, it has been 
suggested  that it is the contaminant protein during manufacturing process, e.g. albumin, 
rather than the SK molecules that causes the activation of immune system (Skopál et al. 
2000). Thanks to these fundamental studies, there is a considerable potential to improve 
the therapeutic efficacy of SK in the future. 
 
Although the original SK formulation does not have the blood clot targeting function and 
may not be an ideal thrombolytic agent for clinical use, as a high molecular weight 
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thrombolytic agent (60 kDa) that is able to convert plasminogen into plasmin, the 
feasibility of TSL system with SK molecules should be a strong indication of the 
compatibility of the system with tPA molecules.  Hence, the feasibility of TSL and related 
preparation methods was initially studied using SK as a pilot model. After the successful 
preparation of SK-encapsulated TSL (i.e. SK-TSL), an attempt would be made to 
prepare tPA-encapsulated TSL using the optimized preparation method obtained with 
SK-TSL.  
 
In addition, given the discovery of the 59-NH2-terminal residues on SK, it is still possible 
to develop a rSKΔ59 encapsulated TSL that may offer a similar benefit to what is 
expected from tPA-TSL, and the development of SK-TSL may provide valuable data that 
can aid such a potential application in the future.  
 
 
5.2.2. Quantification method for thrombolytic agent 
 
The thrombolytic effect of SK and tPA lies in their ability to produce plasmin through 
peptide bond cleavage in plasminogen. Although SK and tPA molecules interact with 
their substrate in different manners, the amount of the end product of the enzymatic 
reactions (i.e. plasmin) is directly proportional to the concentration of thrombolytic agent 
available (Grierson et al. 1987, Kim et al. 2009). Hence, using plasmin-specific 
oligopeptide substrate (i.e. s-2251TM), the conversion rate of plasminogen to plasmin can 
be used to quantify the thrombolytic agent concentration. The structure of s-2251TM and 
the related reaction to quantify plasmin are illustrated below: 
 
 
Where Val represents valine. Leu represents leucine. Lys represents lysine. pNA 
represents para-nitroaniline. D indicates molecule is D isomer according to spatial 
configuration of atoms.  
. 
Similar to the specific peptide bond to be targeted on the fibrin network, the peptide bond 
between lysine and p-nitroaniline (i.e. pNA) on the s-2251TM can be selectively cleaved 
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by plasmin molecules (Friberger et al. 1978). Such an amidolytic effect releases NH2-
pNA molecules, a chromogenic molecule having a high absorption coefficient at 405 nm 
(Budzynski 2001). Therefore the concentration of plasmin, and indirectly, the effective 
concentration of thrombolytic agent can be obtained based on the enhancement of 
UV/Vis intensity at 405 nm. It has to be emphasized here that although a detailed study 
on the substrate-plasmin interaction is beyond the scope of the project, the exclusive 
selectivity of  s-2251TM towards plasmin against other types of protease (e.g. tPA and 
SK) has been determined (Budzynski. 2001). Hence, the break-up rate of the peptide 
bond in s-2251TM is a reasonable representation of the level of plasmin concentration. 
Plasminogen and s-2251TM are added in excessive amount to ensure that the 
concentration of thrombolytic agent is the limiting factor of the assay.  
 
 
5.2.3. Vesicle preparation method for thrombolytic agent-TSL 
 
Unlike amphiphilic doxorubicin that can be actively loaded into liposomes through pH 
gradient, until now, proteins can only be passively loaded into liposomes during the 
formation of vesicles or their water compartments (to be detailed below) (Walde et al. 
2001).  Leaving aside the special interaction between target solute and phospholipid 
molecules (Colletier et al. 2002), the encapsulation capacity of a vesicle during passive 
encapsulation is influenced by the volume of its hydrophilic compartment (i.e. internal 
water space) and its engulfing mechanism (i.e. the equilibrating state between 
phospholipid assemblies and solute molecules throughout the vesicle preparation 
process). Both parameters are largely determined by the vesicle preparation method 
adopted. 
  
5.2.3.1. Ideal physical characteristics of vesicle for high encapsulation capacity 
 
In general, the size of the internal compartment of the vesicle, expressed as the volume 
of entrapped aqueous space per lipid (µl/mg), is affected by the lamilarity (i.e. the 
number of lamellae in the vesicles) and the size of the vesicle. Multilamilar vesicles have 
an inferior internal water space compared with their uni-lamilar counterparts as a result 
of the low participation of multilamilar lipid in the internal lamellae and close apposition of 
adjacent concentric bilayers that further restrict the internal water space (Szoka et al. 
94 
 
1978).  On the other hand, larger vesicles have higher internal water space than smaller 
vesicles as the size of the vesicles is proportional to the ratio of the vesicle surface area 
to encapsulated volume (Szoka et al. 1978).  Hence, in order to maximize the volume of 
the internal water compartment of vesicles, it is desirable to prepare vesicles with a large 
particle size and low lamilarity.   
 
5.2.3.2. Available preparation methods for large vesicles with low lamilarity 
 
Currently, ethanol injection (EI), detergent dialysis (DD), freeze-thawing cycle treated 
MLV (MLV-FAT) and   reverse phase evaporation (REV) are the four main preparation 
methods available to produce large vesicles with low lamilarities (Walde et al. 2001).  
 
EI is considered to be one of the simplest methods to prepare large unilamilar vesicles. 
In brief, an ethanol solution containing the lipids is injected rapidly into an excess of 
saline or other aqueous medium to directly form vesicles (Walde et al. 2001). The target 
solute molecules are encapsulated upon formation of vesicles. The encapsulation 
efficiency of EI, however, suffers as a result of the limited lipid concentration that can be 
utilized during the preparation process. This is due to a combination of low lipid solubility 
in ethanol and a limited amount of ethanol solution that can be introduced into the 
medium (generally no more than 10v/v% ) (Pons et al. 1993).  
  
During DD preparation, specially selected detergent molecules are mixed with 
phospholipids and aqueous solution containing the target solute molecules, forming 
micelles composed of lipid and detergent. Detergent molecules are then removed by 
dialysis and their departure from the micelle leads to the formation of liposomes (Jiskoot 
et al. 1986). Similar to EI, the target solute molecules are expected to be encapsulated 
during the formation of vesicles. Similar to EI, the low concentration of phospholipid is 
one of its main drawbacks as a result of the low concentration of detergent (and hence 
phospholipid) aqueous medium can tolerate (Wacker et al. 1998).  
 
MLV-FAT is a method that aims to maximize the encapsulation efficiency of MLV initially 
prepared by simple hydration through the utilization of freeze-thawing cycle (FAT) 
(Walde et al. 2001).  The multilamilar characteristics of MLVs limit the number of lipid 
molecules that are available to encapsulate the target solute molecules. Furthermore, 
95 
 
the overall concentration of the solute encapsulated during lipid hydration is inferior to its 
original medium, further reducing the encapsulation efficiency of MLV (Mayer et al. 
1985).  By applying FAT, MLVs are repeatedly broken up and reformed, reducing the 
lamilarity of vesicles (Traïkia et al. 2000).  In addition, during the breaking up and 
reformation of vesicles, solute molecules are in constant equilibrium across the 
membrane throughout the FAT process. This provides more opportunities for the vesicle 
to engulf solute molecules at their original concentration and to increase the chance of 
cross-membrane solute equilibrium, whereas with EI and DD the vesicles only engulf 
solute molecules once. In REV procedure, vesicles are formed in a two-step organic 
solvent removal process: initially, lipid-containing organic solvent (immiscible with water) 
is mixed with water containing the target solute molecules and a reverse micelle 
emulsion is formed by mechanical methods. In the second step, the organic solvent is 
removed from the mixture under vacuum (Szoka et al. 1978).  While the initial reverse 
micelle is disintegrated at this step, the remainder of phospholipid molecules fuse 
around the remaining micelles (becoming bilayers) and eventually form vesicles (Szoka 
et al. 1978). The schematic of the REV process is illustrated in Figure 5.1. 
 
 
 
Figure 5.1. A schematic of the preparation process of REV using water-immiscible phase 
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5.2.3.3. The role of solute-engulfing mechanism in encapsulation capacity of vesicles   
 
Although the physical characteristics of vesicles play a role in determining the 
encapsulation capacity during passive encapsulation, they only partly account for the 
encapsulation ability of vesicles.  Compared with MLV prepared by simple hydration, the 
application of FAT has been shown to significantly increase the internal water volume 
from 0.47 µl/ml to 5 µl/ml (Mayer et al. 1985) and the amount of encapsulated sucrose 
by 10-fold (Szoka et al. 1978), using EPC/Cholesterol vesicle as a membrane model. On 
the other hand, while large unilamilar vesicles prepared by fusion method (i.e. small 
unilamilar vesicles are fused into big unilamilar vesicles) have similar internal water 
volume to those prepared with MLV-FAT, their ability to encapsulate sucrose is only 
comparable only to that of MLV vesicles (i.e. around 5%) (Szoka et al.1978). The 
significant difference in encapsulation performance among vesicles that have similar 
physical characteristics indicates the importance of vesicle preparation method as it 
determines the mechanism of solute encapsulation during vesicle formation. Based on 
this previous work (Szoka et al. 1978), it is believed that REV is a more promising 
method for high encapsulation capacity of thrombolytic agent, due to the unique 
mechanism of solute encapsulation during vesicle preparation or formation of the water 
compartment of the liposome.  
 
 
 
5.2.3.4. REV method for the preparation of thrombolytic agent-TSL 
  
In most of the vesicle preparation methods mentioned previously, solute molecules are 
encapsulated either during the initial formation (e.g. REV and DD) or re-formation of 
vesicles (MLV-FAT).  Apart from the restriction on lipid concentration, vesicles prepared 
by EI and DD can only engulf the target solute once (i.e. during the formation of lipid) 
and it has been reported that such a one-step encapsulation process is not sufficient to 
engulf the target solute medium at its original concentration (Mayer et al. 1985).  
Compared with EI and DD, the lipid concentration that can be used during MLV-FAT 
preparation process is not limited and can be as high as 100 mg/ml (Mayer et al. 1985). 
In addition, the reformation of vesicles provides an opportunity for vesicles to re-
equilibrate with the solute medium, reducing the percentage of vesicles that originally 
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have a sub-solute concentration. As a result, the ability of vesicles to engulf solute 
molecules prepared by MLV-FAT is significantly higher than vesicles prepared by the 
other two methods, making MLF-FAT a method of choice for the preparation of 
thrombolytic agent-encapsulated TSL. However, as large unilamilar vesicles prepared by 
the fusion method are unable to engulf more small molecular weight solutes than their 
multilamilar counterparts, it is still possible that the reformation of vesicles during FAT 
process is unable to engulf high molecular weight thrombolytic agent (Szoka et al. 1978).  
 
In contrast to the other three preparation methods that engulf their solutes during the 
formation or re-formation of vesicles, encapsulation of the target solute by REV occurs 
during the formation of the water compartment (i.e. the formation of reverse micelle).  
During this meta-phase, nearly all the hydrophilic phase, along with all the solute 
molecules, are considered to be isolated from the organic phase using reverse micelles 
as a barrier and become a potential internal water compartment with a solute 
concentration that matches its original hydrophilic environment (Szoka et al. 1978). 
Although it is possible that the initially formed water compartment may disintegrate 
during the subsequent formation of vesicles, the addition of adequate lipid molecules 
can minimize the likelihood of undesirable collapse of the initially formed water 
compartment and maximize the amount of encapsulated target solutes.  From herein the 
amount of thrombolytic agent encapsulated into the liposome will be referred to as D/L 
ratio (i.e. thrombolytic agent/lipid ratio, IU/mg). 
 
In order to maximize the D/L ratio, it is believed that REV offers considerable advantage 
over MVL-FAT as the target solute concentration in the water compartment is 
comparable to that in the original hydrophilic phase and no additional effort is needed to 
maximize its concentration, as is required in the MVL-FAT vesicle preparation process.   
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5.3. Preparation procedure of thrombolytic agent-encapsulated TSL or LTSL  
 
This section describes in detail the work carried out in order to determine the suitable 
REV procedure for thrombolytic agents, as well as the relevant analytical process.   
 
 
5.3.1. Preparation method for thrombolytic agent using reverse phase evaporation 
method  
 
Stock lipid chloroform/methanol (1:1 V/V) solutions were mixed and solvent was then 
removed using a rotary evaporator to form a dried thin layer. Dried lipid film (12.5 mg of 
total lipid) was dissolved with chloroform and mixed with tris buffer (20 mM tris, pH 9) 
containing either SK (10 KIU/ml) or tPA (300 KIU/ml).  Mixture was then vortexed for 5 
minutes and chloroform was removed from mixture through vacuum. Vesicles were 
eventually separated from free thrombolytic agent molecules on a Sepharose CL-2B 
column (0.8 cm × 10 cm) equilibrated with tris buffer.  
 
5.3.2. Quantification of SK and determination of D/L ratio of SK-encapsulated liposome 
 
D/L ratio (IU/mg) of SK-encapsulated vesicles was obtained by total solubilization of the 
vesicles. At first, liposome was lysised by adding 1 v/v % Triton X-100. The amount of 
SK was obtained by s-2251TM-based amidolytic assay; 100 µl of lysised liposome 
sample was mixed with tris buffer equilibrated at 30oC using water bath. 20 µl of 
plasminogen (120 IU/ml) and soybean trypsin inhibitor (SBTI) (0.5 mg/ml) were 
introduced into the buffer and mixture was allowed to incubate for 5 min. Then, 200 ml of 
S-2251 TM (1.98 mg/ml) was added and mixture was further incubated for another 5 min.  
The mixture was then put in ice bath for 5 min and its UV/Vis reading at 405 nm was 
obtained to quantify the amount of SK. The percentage of SK that was considered to be 
encapsulated inside the liposome was obtained by comparing the amount of SK prior to 
and after the solubilisation of liposome. 
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5.3.3. Quantification of tPA concentration and determination of D/L ratio of tPA-
encapsulated liposome 
 
Similar to SK-encapsulated vesicles, D/L ratio of tPA-encapsulated vesicles was 
obtained by total solubilisation of the vesicles. At first, liposome was lysised by adding 1 
v/v % Triton X-100. The amount of tPA was obtained by the same s-2251 TM -based 
amidolytic assay with slight modification; 100 µl of lysised liposome sample was mixed 
with 1 ml of tris buffer at room temperature and was put in the UV/vis spectrometer. 
Plasminogen and S-2251TM solution were put into the solution. The slope of UV/Vis 
signal reading at 405 nm between 5 and 10 min was used to quantify the amount of tPA. 
The percentage of tPA that was considered to be encapsulated inside the liposome was 
obtained by comparing the amount of tPA prior to and after the solubilisation of 
liposome. 
 
 
5.3.4. Thermal sensitivity test of SK or tPA-encapsulated vesicles  
 
The release behaviour of both vesicles at various temperatures was obtained by directly 
heating liposome solutions in a temperature-equilibrated water bath for 5 min.  Liposome 
solution was then allowed to cool down in a room temperature-equilibrated water bath 
for another 5 min.  The amount of thrombolytic agent detectable after heating is 
quantified using the amidolytic method described in section 5.3.2.or 5.3.3. The 
percentage release of thrombolytic agent was calculated using the following equation 
 
 
% thromobltyic agent release =
𝐹𝐼 − 𝐹0
𝐹𝑓𝑢𝑙𝑙 − 𝐹0
× 100% 
 
Where F0 is the amount of thrombolytic agent detected prior to heating, FI is the amount 
of thrombolytic agent detected after heating, Ffull  is the amount of thrombolytic agent 
detected after complete release of thrombolytic agent using 1 v/v % Triton X-100. 
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5.3.5. Determination of phase transition temperature and particle size of tPA-TSL 
 
Stock tPA-TSL solution (10 µl) was added into aluminium pan made for DSC 
measurement and pan was clip-sealed. The sample-containing pan was then introduced 
into the sample cell of differential scanning calorimeters (Dsc q 2000, TA instrument). 
Empty sample aluminium pan was used as reference sample.  The heat flow of sample 
from 30 oC to 60 oC was recorded.  
 
Stock tPA-TSL solution (100 µl) was diluted in buffer solution (1 ml, Tris buffer) and was 
transferred into BrandTech® disposable UV Cuvette. Cuvette was then transferred into 
sample cell of PCS (Zetasizer Nano S, Malvern).  Refractive index was set at default 
liposome solution and incubation temperature was set at 25 oC. Detection angle was set 
at 173 o. Z-average size (hydrodynamic diameter, nm) and pDI (polydispersity index) are 
the two parameters used in the project to describe the particle size of liposomes. The 
data was based on the intensity distribution of measured solution.  
 
 
 
5.4. Results and discussion 
 
5.4.1. Feasibility of SK-encapsulated LTSL  
 
SK molecules were encapsulated into LTSL vesicles using REV process and the D/L 
ratio of SK in the produced SK-LTSL was determined and illustrated in Figure 5.2. As 
can be seen, 1 mg of lipid was able to incorporate 88 IU of SK molecules. Among the 
total incorporated SK molecules, 55% was unavailable for plasminogen interaction 
during s-2251TM based assay and was considered to be “encapsulated”. 
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Figure 5.2.  D/L ratio (IU/mg) of SK-encapsulated LTSL (n=3). Amount of SK was 
determined using s-2251
TM
 based amidolytic assay. 55% of SK was considered to be 
encapsulated and was unavailable to convert plasminogen till complete solublization of 
liposome.  
 
The extent of SK release from LTSL vesicles at various temperatures was determined. 
As shown in Figure 5.3, vesicles were able to release majority of the encapsulated SK 
molecules (~90%) after 5 min heating at 45°C. The structure and mechanism of the 
release behaviour of SK-LTSL vesicles, however, are somewhat different from the 
doxorubicin-encapsulated LTSL vesicles prepared by extrusion method.  
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Figure 5.3.  The extent of SK release from LTSL at 42 and 45
o
C (n=3). Stock SK-TSL 
solution was heated at predetermined temperature for 5 min and the amount of SK 
molecules was determined using s-2251 based assay. Heating at 45 
o
C for 5 min resulted 
in complete release of encapsulated SK. 
 
5.4.2. Feasibility of tPA-encapsulated TSL  
 
Having demonstrated the applicability of REV for encapsulation of SK, the same 
procedure was applied to tPA (the target thrombolytic agent of the project), but the 
formulation of vesicle was changed from LTSL to a more stable TSL due to the higher 
MW of tPA, which may destabilize the membrane. When determining the thermal 
sensitivity of tPA-TSLs, heating time was increased to 7 minutes as it was expected that 
high MW  molecules might hinder their release from TSLs.    
 
The drug to lipid ratio (D/L ratio, IU/mg), particle size and phase transition temperature of 
tPA-TSLs were determined using the methods described in section 5.3.  The obtained 
results are presented in Table 5.1, which demonstrates that tPA-TSLs were able to 
encapsulate 5.07 IU (0.016936 mg) of tPA per mg of lipid.  According to the measured 
heat flow, tPA-TSL had a phase transition temperature (Tm) of 41.79 
oC, similar to the Tm 
of dox-TSLs (presented in Table 3.2). Interestingly, the hydrodynamic diameter of tPA-
TSLs was significantly larger (2286 nm) in comparison with blank REV-prepared TSLs  
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(538 nm), suggesting that the incorporation of tPA molecules altered the physical 
properties of liposome membrane. In addition, tPA- TSLs released 75% of encapsulated 
tPA upon 7 minutes heating at 45oC. 
 
Table 5.1.  Characterization of tPA-TSLs and blank TSLs prepared by REV method 
Type of formulation and 
component  
 
D/L ratio, 
(IU/mg)   
 
Particle size 
Tm (
o
C) 
% of 
tPA 
release 
after 
heating  
Hydrodynamic 
diameter (nm) 
 
Polydispersity 
index 
 
              tPA-TSL  
DPPC:DSPE.PEG.2000 
(96:4) 
 
5.07         
   (1.10) 
(n=3) 
   
 2286 
 
(34) 
(n=3) 
 
0.5315 
(0.4293) 
(n=3) 
 
42.1799 
(0.00121) 
(n=2) 
 
 
75.1 %
 
 (11.2) 
(n=4) 
 
Blank-TSL  
DPPC:DSPE.PEG.2000 
(96:4) 
N/A 
 
538
5
   
(44) 
 
0.7953
5
 
(0.159) 
N/A 
 
 
N/A 
 
 
 
 
 
 
5.4.3. Potential release mechanism of tPA from TSL upon heating  
 
Irrespective of its potential release behaviour, thermal sensitive liposomes prepared by 
extrusion method (~100 nm) have been reported to retain their morphology after heating 
(de smet et al. 2013).  Different from the small molecular-encapsulated TSLs (e.g, 
doxorubicin, etc), thrombolytic agent-encapsulated thermal sensitive liposome prepared 
here are likely to have experienced irreversible destruction upon heating. This was 
based on initially observed turbidity changes of the heated SK-LTSL liposome solution 
during D/L determination assay, in which 100 µl of heated stock liposome solution was 
added into 1 ml of Tris buffer. It was noticed that the appearance of mixture after the 
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addition of heated liposome solution was much clearer compared to that of the unheated 
liposome. This resembled the turbidity reduction of triton X-100 treated liposome 
solution. 
 
In order to find the potential mechanism of tPA release from tPA-TSLs upon heating, the 
particle size of tPA-TSLs solution prior to and after 7 minutes heating at 45 oC was 
determined and shown in Figure 5.4.A.  The results show that  the particle size of tPA-
TSLs reduced significantly from 2286 nm to 1010 nm after heating, indicating that tPA-
TSL might have been destroyed.  In contrast to tPA-TSLs, particle size reduction of 
blank REV-prepared TSLs (TSLs encapsulated with pure buffer solution) was much less 
significant, reducing from 538 nm to 447 nm. This indicates that the presence of tPA 
molecules is critical to the irreversible morphology change of tPA-TSL upon heating. 
Changes in particle size of  tPA-TSLs after addition of triton X-100 are presented in 
Figure 5.4.B as a reference. 
 
(A)                                                                                                                 (B) 
Figure 5.4. Changes in particle size of tPA-TSLs and blank TSLs prior to and after heating 
at 45 
o
C for 7 minutes (A) (n=3). Changes in particle size of tPA-TSLs prior to and after the 
addition of triton X-100 (B) (n=3).  
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It has been well documented that different types of proteins can associate with different 
sites of the lipid membrane, influencing the properties of the resultant protein-lipid 
complex:  the small ionic permeability of liposome has been reported to be drastically 
changed, either as a result of liposome-protein association or structural change of 
protein in response to temperature rise (Kimelberg. 1976).  Although we cannot verify 
the actual state of encapsulated tPA molecules (i.e. whether it was truly encapsulated in 
the interior of the liposome, or it was in a “unavailable state” to the assay), it is 
speculated that, upon heating, the lipid-associated protein causes irreversible 
dissociation of REV membrane rafts between protein molecules, which results in the 
eventual destruction of the liposome.  
 
 
5.4.3.1. Lipid-protein interaction  
 
Depending on their hydrophobicity, membrane-associated proteins have various 
preferable lipid-interaction sites and have been initially categorized into three groups. 
Proteins in group I are charged water soluble proteins that  interact solely with head 
groups of phospholipids (Papahadjopoulos et al. 1975). Groups II proteins are less 
hydrophilic than group I proteins and interact with both the hydrophilic head group and 
bilayer face (Papahadjopoulos et al. 1975). Group III are composed of water-insoluble 
apolipoproteins that interact mainly with the hydrocarbon part of membrane 
(Papahadjopoulos et al. 1975).  Transmembrane proteins were later defined by 
Kimelberg et al as the fourth type of proteins due to their ability to interact with head 
group on both monolayers of the membrane (Kimelberg. 1976).  As will be discussed 
below, both tPA and SK interact with the head group as well as the apolar region of the 
lipid and are considered as group II proteins.  
 
It was initially hypothesized that, by determining the preferable interaction site of the 
protein, the impact of addition of protein on/into the membrane can be predicted and 
summarized: while the interaction between group I and the head group of lipid had little 
influence on the permeability of membrane, penetration of the other types of protein 
(groups II, III and IV) into the lipid membrane has been predicated to result in a 
substantial expansion of originally closely packed membrane and enhancement of 
vesicle permeability (Papahadjopoulos et al. 1975).  
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It was later discovered that, in addition to the category of the protein, changes in 
membrane property also depended strongly on the structure of the lipid itself: being 
considered as a group II protein, gramicidin S protein was only capable of altering the 
thermaltropic behaviour of anionic lipid and neutral lipid that have strong shielding at 
their positive sites (e.g. DPPC) (Prenner et al. 1999). Such proteins however, have little 
effect on 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine (lipid with a low shielding 
strength) (Prenner et al. 1999). Two other type II group proteins, cytochrome C and A1 
protein also show the reliance of anionic group to alter the property of the membrane 
(Papahadjopoulos et al. 1975).   As a result, the structure of both lipid and protein should 
be taken into account when predicting the likely alteration of membrane property.  
 
 
5.4.3.2. Hypothesis of tPA-induced TSL destruction upon heating  
 
Possibly due to the high shielding of amine group, DPPC behaves as a pseudo-anionic 
lipid and has been reported to interact with group II proteins such as cytochrome c, 
gramicin S and result in the modification of thermotropic behaviour of liposomes.  Given 
the type II protein nature of tPA molecules, the membrane property of DPPC-based TSL 
system is likely to be altered as a consequence of the insertion of tPA molecules, 
resulting in expansion of membrane area. 
  
In summary, the destruction of tPA-TSL upon heating may be the result of the following 
two combinations:  
 
1. Interaction between protein and lipid membrane 
2. Melting of lipid chain upon heating 
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5.4.4. Hypothesis of structure of tPA-TSL 
 
As defined in section 5.3.3., “encapsulated tPA molecules” is a term  used to represent 
the population of tPA molecules that is not available to plasminogen prior to either 
heating or destruction of vesicles using Triton X-100.  While it is hoped that the 
unavailability of encapsulated tPA molecules to plasminogen is a result of them being 
truly encapsulated in the interior of liposomes, given the observed interaction between 
tPA molecules and membrane, one cannot rule out the possibility that interactions 
between the hydrophobic active sites of tPA molecules and the apolar-region of the lipid 
(i.e. interface and/or hydrocarbon tail region) may prevent the protein being available to 
plasminogen (pseudo-encapsulation).  The potential protein-PEG layer interaction is 
another possible pseudo-encapsulation state that may contribute to the unavailability of 
tPA molecules to plasminogen.  Using the current thrombolytic agent quantification 
method (i.e. s-2251TM-based assay), it was not possible to distinguish whether the 
unavailability of tPA molecules was the results of either “true encapsulation” or “pseudo-
encapsulation” of the protein.  
 
5.5. Summary 
 
By the end of the project, it has been demonstrated that both SK and tPA molecules can 
be encapsulated into DPPC-based vesicles and the encapsulated agents can be 
released after heating at 45oC. Based on observed particle size change of tPA-TSLs 
prior to and after heating, it has been hypothesized that thrombolytic agent was released 
from vesicles as a result of irreversible destruction of liposome upon heating. This 
mechanism of release is different from TSL systems that encapsulate small MW 
molecules such as doxorubicin. Such a unique release mechanism is believed to be a 
combined result of protein insertion into the liposome membrane and melting of lipid 
chain upon heating. 
.  
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6. Conclusions  
In this chapter, the major achievements made in this project are summarized, together 
with critical comments on the current formulation and results obtained. This is followed 
by a summary of the intrinsic limitations of the analytical methods employed, and 
suggestions for future work.  
 
 
6.1. Main conclusions 
6.1.1. Development of lysolipid-free doxorubicin-TSL 
 
The most significant achievement in this part of the project is the development of a 
lysolipid-free TSL formulation for the encapsulation of doxorubicin.  By directly heating 
dox-TSLs into buffers solution that are temperature-equilibrated at hyperthermia (45 oC), 
around 80% of encapsulated doxorubicin could be released within 10 seconds. As the 
formulation does not contain lysolipids, dox-TSLs are free from the risk associated with 
lysolipid-induced leakage at physiological temperature. Hence, the doxorubicin-TSL 
produced using this formulation has the potential to become a viable substitute for the 
current doxorubicin-LTSL formulation. 
 
The second achievement is the discovery that selection of incubation temperature (30oC- 
36 oC) contributes heavily to achieving high D/L ratio of dox-TSLs.  As a result, the D/L 
ratio of dox-TSLs prepared in the current study is 2 times the D/L ratio that reported in 
the existing publications. This is done by increasing the inward movement of doxorubicin 
molecules into the liposome, while limiting the outflow of H+ molecules. Moreover, it has 
been found that the permeability changes of TSLs to unprotonated doxorubicin within 
30oC- 36 oC temperature range coincides with the initiation of membrane transition from 
solid phase to ripple phase (at ~32oC) (Heimburg. 1998). This finding may provide us 
insights into the intrinsic instability of DPPC-based TSL under in vivo conditions. Based 
on the analysis presented in Chapter 3, there is a possibility that the application of DPPC 
as a membrane component may itself compromise the protective functionality of 
PEGlyation and hinder the further optimization and application of thermal sensitive 
liposomes.   
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A limitation of this study is the lack of detailed information on membrane transition.  In 
the ground-breaking paper that described the application of lysolipid in DPPC-based 
liposome, Anyarambhatla and Needham provided detailed DSC scan of TSL membrane  
which clearly demonstrated the occurrence of pretransition of DPPC TSL membrane 
(from solid phase to ripple phase) by the presence of endothermic peak at ~37 oC. A 
similar peak in the DSC scan was also obtained by other groups (Heimburg. 1998, Wu et 
al. 2011). On the other hand, change in heat flow during pretransition was several orders 
lower than that during the main transition of membrane. As presented in appendix VII, 
the observed heat flow changes of main transition in the current study (1.5 MW ) was 7 
times lower than that observed by Anyarambhatla and Needham (~10 MW) . Therefore, 
it is highly likely that the lack of membrane transition information in our measurements 
was due to the low concentration of liposome.  
 
 
 
6.1.2. Development of lysolipid-free tPA-TSL 
 
The most significant achievement in this part of the project is the development of DPPC-
based thermal sensitive liposome for encapsulation and release of thrombolytic agents, 
of which SK and tPA have been tested. This is the first time lysolipid-free TSLs have 
been shown to have the capacity to encapsulate and release high molecular weight 
therapeutics. It has also been observed that the release mechanism of SK or tPA 
encapsulated-TSL is different from that of small molecule-encapsulated TSL, It is 
commonly believed that the after the heating process, small molecule-encapsulated 
TSLs retained their integrity (de Smet et al. 2013). However, the SK or tPA-loaded TSL 
vesicles produced in this project are believed to have experienced irreversible 
destruction upon heating, thereby releasing the encapsulated contents. This is based on 
the observed particle size changes of liposome solution prior to and after heating.  
 
The tPA-TSL developed in this project is a combined product of 3 separate formulations:  
 Liposomes that have fibrin-targeting capability through the direct incorporation of 
tPA into the liposome membrane (e.g. tPA-ELIP). 
 
 PEG.2000-based stealth liposome containing 5 mole % of membrane.  
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 DPPC-based thermal sensitive liposome.   
 
While the original intention was to keep all three functionalities described above in one 
formulation, it is possible that the in vivo stability of the tPA-TSLs was compromised by 
this combination, largely as a result of direct insertion of tPA for fibrin-targeting 
capability: Upon binding onto the fibrin, the affinity of tPA towards plasminogen 
increases significantly (Nieuwenhuizen. 1994), which is accompanied by the breakage of 
tPA from a one-chain protein molecule into a two-chain molecule (Thorsen. 1992). As a 
considerable amount of proteins might be in “pseudoencapsulation state” with the active 
hydrophobic part of the protein being inside the membrane, it is possible that the tPA-
incorporated membrane may be disrupted due to the conformation change of tPA 
proteins upon fibrin binding resulting in either premature leakage of tPA prior to heating 
or loss of thermal sensitivity of liposome.  Furthermore, since DPPC is the main-
component of the tPA-TSL, the membrane is already in a relatively loose ripple phase, 
further weakening the disruption resistance of membrane against tPA-conversion.  
 
In summary, similar to the doxorubicin-TSL, the combined effect of DPPC-based thermal 
sensitive liposome and direct insertion of tPA for fibrin-binding may reduce the TSL 
stability at physiological temperature.  
 
6.2. Limitations of the analytical methods employed  
 
The analytical methods adopted in this project were selected based on  their established 
application, wide  usage and availability. Nevertheless, each analytical method has its 
own intrinsic limitations that may affect its ability to accurately determine   the 
parameters of interest. These are explained below.  
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6.2.1. Limitations of doxorubicin quantification method  
 
The self-quenching characteristic of doxorubicin was exploited to determine the D/L ratio 
of doxorubicin and the release behavior of doxorubicin-encapsulated vesicles at various 
temperatures: the initial fluorescence intensity (F0) was used to represent the initial 
concentration of solute (C0) and was quantified using the relevant calibration curve. 
Although widely used in liposome research, this method cannot measure C0 directly, and 
the measured F0 is a result of either:  
 
 Accumulated fluorescence signal of liposome with quenched  concentration of 
solute encapsulated, or 
 
 Accumulated fluorescence signal of liposome with unquenched concentration of 
solute inside the membrane 
 
It is the stacking of solutes at high concentrations that leads to the shield of fluorophore 
and the reduction (i.e. quenching) of fluorescence signal. After being encapsulated in the 
liposome, however, the stacked solutes become isolated from other populations of 
stacked solutes that are encapsulated in the other vesicles. Due to the disappearance of 
stacking effect among individual solute aggregates, C0 increases with increasing 
liposome concentration. On the other hand, it is also possible that, solutes may be 
incorporated in the membrane of liposome at unquenched concentration and the F0 is 
the accumulated fluorescence reading of the solute that is associated with the 
membrane.  In either of these cases, F0 is not a good indicator of the initial concentration 
of solute. In most cases though, the fluorescence signal corresponding to the release of 
solute is much higher than F0. Hence, the value for C0 calculated from F0 is a reasonable 
reference point to determine the relative amount of solute release after liposome lysis or 
heating.   
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6.2.2. Limitations of heating method for measurement of thermal sensitivity 
 
Throughout this project, water bath (detailed in appendix II) was used to heat the 
liposome solution to the desired temperature points. However, this simplified heating 
equipment does not mimic the in vivo  condition, in which liposome solution, regardless 
of the temperature at which it is stored prior to administration (e.g. 4oC or 25oC), will first 
enter the circulation which is at normal physiological temperature (~37oC). Through the 
circulatory system, liposome is transported to the target area where it is heated (~42oC).  
Hence, using the heating method adopted here, the initial condition of liposomal 
membrane prior to heating (in solid phase at room temperature) is different from the 
expected in vivo condition (in ripple phase at 37oC) and it is unknown whether the 
release behaviour of liposome will be different if the initial condition of membrane is 
different.  
 
 
6.2.3. Limitations of s-2251TM-based assay for thrombolytic agent quantification 
 
As described in section.5.2.2, through the utilization of plasmin-specific substrate (i.e. s-
2251TM-based assay), tPA and SK were indirectly quantified by the extent of 
plasminogen-plasmin conversion. This method has been used throughout the project to:  
 
 Determine the D/L ratio of SK-TSL and tPA-TSL by comparing the availability of 
thrombolytic agent to plasminogen prior to and after the lysis of liposome  
 Determine the thermal sensitivity of SK or tPA encapsulated TSL by comparing 
the availability of thrombolytic agent to plasminogen prior to and after the heating 
of liposome solution.  
While the result of s-2251TM-based assay  measures the ability of the the thrombolytic 
agent-loaded TSLs to convert plasminogen to plasmin, the assay do not provide some of 
the crucial information about:  
 
 The true nature of tPA or SK unavailability to plasminogen prior to either lysis of 
liposome or heating of liposome solution.  
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 The fibrin-targeting capability of liposome and its subsequent stability.  
The first failure is a result of complicated protein-liposome interaction, as discussed in 
detail in section 5.4.4.1.  The second failure, on the other hand, is due to the 
incompatibility of fibrin and s-2251TM-based assay, as addition of fibrin increases the 
UV/Vis absorption of solution which compromises the ability of s-2251TM-based assay to 
quantify the plasminogen to plasmin conversion.  
 
6.3. Future work 
 
6.3.1. Determination of PEG functionality and fluidity of membrane  
 
The intrinsic instability of DPPC-based TSL at physiological temperature makes it hard 
to further optimize the doxorubicin-TSL formulation.  Since the instability is due to the 
compromised PEG functionality in ripple phase. By increasing Tm of the membrane, it is 
possible that the PEG functionality can be preserved. In the future, the feasibility of this 
theory can be tested first by determining the stability of DPPC:DSPE.2000 liposome at 
sub ripple phase temperature (i.e. below 30oC). This can be accompanied by a detailed 
DSC measurement of the membrane.  
 
6.3.2. Determination of release behavior of TSL at temperatures above Tm 
 
The release behavior of TSL at temperatures above Tm should be carefully studied more 
thoroughly using direct heating method. This will elucidate the role of liquid-solid 
interface in enhancing the thermal sensitivity of TSL at Tm. If the release behavior of 
liposome at temperatures above Tm is comparable to that at Tm, then It may indicate that 
parameters other than liquid/solid interface is responsible for the rapid release of DPPC-
based liposome upon heating. 
 
 
6.3.3. Determination of tPA-TSL stability at physiological temperature  
 
While the thermal sensitivity of tPA-TSLs upon heating was determined in the present 
study, the stability of liposomes at physiological temperature was not measured. 
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However, it is expected that a combined result of tPA incorporation and application of 
DPPC-based membrane may compromise the stability of tPA-TSL. If tPA-TSLs wre 
found to be unstable at physiological temperature, effort would be needed to increase 
the stability of tPA-TSL. The first attempt would be to tighten the packing of membrane 
through the use of lipid with a higher phase transition temperature. In addition, a different 
assay, e.g. fibrin-containing in vitro assay, should be carried out to quantify the amount 
of released tPA. The degree of tPA leakage and thermal sensitivity could be determined 
by the reduction of fibrin loss, rather than the UV/Vis absorption change in S-2251 based 
assay.  
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Appendix I- List of chemicals used and their abbreviations 
Function of 
chemical during 
assay 
Abbreviation 
in text 
Full name of chemicals 
Manufacture 
and 
catalogue 
number 
Purity 
Size exclusion 
column for 
liposome/solute 
separation 
Sephadex G-
25 column 
Disposable PD-10 Desalting 
Columns 
 
GE Healthcare 
(7-0851-01) 
≥98% 
 
Sepharose
®
 
CL-2B column 
 
N/A 
Sigma-Aldrich  
(CL2B300) 
N/A 
Lysis of liposome 
Triton
™
 X-100 
 
4-(1,1,3,3-
Tetramethylbutyl)phenyl-
polyethylene glycol 
Sigma-Aldrich  
(X100) 
N/A 
Chemicals for 
tPA/SK 
quantification 
Plasminogen 
Plasminogen, Human Plasma 
 
Merck KGaA, 
Darmstadt, 
Germany 
(528175) 
≥95% 
SBTI Trypsin Inhibitor from Glycine 
max (soybean) 
 
Sigma-Aldrich  
(T2327) 
≥98% 
s-2251 
D-Val-Leu-Lys 4-nitroanilide 
dihydrochloride 
plasmin substrate 
 
Sigma-Aldrich  
(V0882) 
N/A 
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Full name  Full name 
Manufacture and 
catalogue number 
Purity 
Phospholipid 
DPPC 
1,2-dipalmitoyl-sn-glycero-3-
phosphocholine 
Avanti Polar lipid, 
Alabaster, AL, USA 
(850355P) 
>99 
MPPC 
1-palmitoyl-2-hydroxy-sn-
glycero-3-phosphocholine 
 
Avanti Polar lipid, 
Alabaster, AL, USA 
(855675P) 
>99 
MSPC 
1-dipalmitoyl-sn-glycero-3-
phosphocholine 
Avanti Polar lipid, 
Alabaster, AL, 
USA(855775P) 
>99 
DSPE.2000 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-
[methoxy(polyethylene 
glycol)-2000 
Avanti Polar lipid, 
Alabaster, AL, USA 
(880120P) 
>99 
 
DSPC 
 
 
1,2-distearoyl-sn-glycero-3-
phosphocholine 
Avanti Polar lipid, 
Alabaster, AL, USA 
(850365C) 
>99 
 
HSPC 
 
 
L-α-phosphatidylcholine, 
hydrogenated (Soy) 
 
Avanti Polar lipid, 
Alabaster, AL, USA 
(840058P) 
>99 
MRI contrast 
agent-
incorporated 
lipid 
Gd.DOTA.DSA 
Gadolinium (III) 2-{4,7-bis-
carboxymethyl-10-[(N, N-
distearylamidomethyl-N`-
amidomethyl]-1,4,7,10-tetra-
azacyclododec-1-yl}-acetic 
acid 
Synthesized by 
previous research 
group 
N/A 
Gd. PE-DTPA 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-
diethylenetriaminepentaacetic 
acid (gadolinium salt) 
Avanti Polar lipid, 
Alabaster, AL, USA 
(791275P) 
 
>99 
Other lipid 
component 
Cholesterol 
 
3β-Hydroxy-5-cholestene 
Sigma-Aldrich  
(C8667) 
>99 
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Solute  
Abbreviati
on of 
chemical 
Full name 
Manufacture 
and catalogue 
number 
Purity 
Hydration 
buffer 
For 
doxorubici
n and 
calcein 
Ammonium 
phosphate 
Ammonium phosphate monobasic 
Sigma-Aldrich  
(216003) 
≥98% 
 
HEPES 
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid 
Sigma-Aldrich  
(H3375) 
≥99.5% 
 
Sodium 
chloride 
N/A 
Sigma-Aldrich 
(S9888) 
≥99% 
 
Hydration 
buffer 
For SK 
and tPA 
 
Tris buffer 
Tris(hydroxymethyl)aminomethane 
 
Sigma-Aldrich  
(252859) 
≥99.8% 
 
 
Target 
encapsulat
ed solute 
 
 
 
 
 
 
Doxorubici
n 
Doxorubicin hydrochloride 
 
Sigma-Aldrich  
(D1515 ) 
 
98.0-102.0% 
Calcein  
Bis[N,N-
di(carboxymethyl)aminomethyl]fluo
rescein disodium salt, Fluorescein-
bismethyliminodiacetic acid 
disodium salt 
 
Sigma-Aldrich  
(21030) 
≥90% 
 
tPA Tissue Plasminogen Activator, 
Human 
 
 
Merck KGaA, 
Darmstadt,Germ
any 
(612200) 
≥300 KU/mg 
protein 
SK Streptokinase from β-hemolytic 
Streptococcus 
 
Sigma-Aldrich 
(S3134) 
≥3,500 units/
mg solid 
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Appendix II  -Information on analytical equipment used in the project  
 
 
Equipment used for doxorubicin-TSL preparation 
and determination 
Model of equipment (supplier) 
 
 
Particle size determination 
 
Zetasizer Nano S 
(Malvern) 
 
Fluscent determination for doxorubicin and calcein 
release 
 
LS-55 spectrometer 
(Perkin Elmer) 
 
Water bath for release study 
Heating bath for rotary evaporator B-491 
(Buchi) 
 
 
Incubator for encapsulation 
Heating bath for rotary evaporator B-491 
(Buchi) 
 
Phase transition determination 
 
Dsc q 2000 
(TA instrument) 
 
SK/tPA-TSL heating 
Heating bath for rotary evaporator B-491 
(Buchi) 
 
UV/Vis measurement for S-2251-based assay 
 
UV-Vis spectrophotometer Lambda 25 
(PerkinElmer) 
 
Stewart assay for lipid determination  
UV-Vis spectrophotometer Lambda 25 
(PerkinElmer) 
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Appendix III- Calibration curve for lipid quantification 
 
 
 
 
Calibration curve of stewart assay. Calibration curve was used for lipid quantification  
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Appendix IV- Calibration curves for doxorubicin quantification 
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R² = 0.9947 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
0 1 2 3 4 5 6
U
V
/v
is
 s
ig
n
a
l 
 
amount of doxorubicin (mg) 
137 
 
 
Appendix V -Calibration curve for SK quantification encapsulated in TSL 
 
 
 
Calibration curve for SK quantification encapsulated in SK-TSL. UV/Vis absorption of 
solution 5 min after the addition of S-2251TM substrate was used to quantify the 
concentration of SK. 
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Appendix VI- Calibration curve for tPA quantification  
 
 
Result of s-2251 TM assay with various tPA concentrations. The slopes are used for tPA 
quantification encapsulated in tPA-TSL containing Gd.lipid.  
 
 
 
 
 
Calibration curve of tPA encapsulated in tPA-TSL containing Gd.lipid. Slopes obtained 
during S-2251 TM assay is used to quantify tPA.  
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Appendix VII- Heating DSC Thermogram of TSL membrane  
 
 
 
Heating DSC Thermogram of TSL membrane DPPC: DSPE.PEG 2000 (molar ratio 96: 4 
) formulation. Lipid amount is around 1.5mg. Heating rate is 1 oC/min.  
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Appendix VIII- Preparation method of liposome gel to prove the feasibility of HIFU 
heating to release F5 
 
 
 
Heating DSC Thermogram of pure DPPC membrane. Lipid amount is around 1.5mg. 
Heating rate is 1 oC/min.  
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